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ABSTR ACT
BACKGROUND: Tobacco smoking is the cause of many preventable diseases and premature deaths in the UK and around the world. It poses enormous 
health- and non-health-related costs to the affected individuals, employers, and the society at large. The World Health Organization (WHO) estimates 
that, globally, smoking causes over US$500 billion in economic damage each year.
OBJECTIVES: This paper examines global and UK evidence on the economic impact of smoking prevalence and evaluates the effectiveness and cost 
effectiveness of smoking cessation measures.
STUDY SELECTION
Search methods: We used two major health care/economic research databases, namely PubMed and the National Institute for Health Research (NIHR) 
database that contains the British National Health Service (NHS) Economic Evaluation Database; Cochrane Library of systematic reviews in health care 
and health policy; and other health-care-related bibliographic sources. We also performed hand searching of relevant articles, health reports, and white 
papers issued by government bodies, international health organizations, and health intervention campaign agencies.
Selection criteria: The paper includes cost-effectiveness studies from medical journals, health reports, and white papers published between 1992 and July 2014, 
but included only eight relevant studies before 1992. Most of the papers reviewed reported outcomes on smoking prevalence, as well as the direct and indirect costs 
of smoking and the costs and benefits of smoking cessation interventions. We excluded papers that merely described the effectiveness of an intervention without 
including economic or cost considerations. We also excluded papers that combine smoking cessation with the reduction in the risk of other diseases.
Data collection and analysis: The included studies were assessed against criteria indicated in the Cochrane Reviewers Handbook version 5.0.0.
Outcomes assessed in the review: Primary outcomes of the selected studies are smoking prevalence, direct and indirect costs of smoking, and the costs and 
benefits of smoking cessation interventions (eg, “cost per quitter”, “cost per life year saved”, “cost per quality-adjusted life year gained,” “present value” or 
“net benefits” from smoking cessation, and “cost savings” from personal health care expenditure).
MAIN RESULTS: The main findings of this study are as follows:
1.  The costs of smoking can be classified into direct, indirect, and intangible costs. About 15% of the aggregate health care expenditure in high-income 
countries can be attributed to smoking. In the US, the proportion of health care expenditure attributable to smoking ranges between 6% and 18% across 
different states. In the UK, the direct costs of smoking to the NHS have been estimated at between £2.7 billion and £5.2 billion, which is equivalent to 
around 5% of the total NHS budget each year. The economic burden of smoking estimated in terms of GDP reveals that smoking accounts for approxi-
mately 0.7% of China’s GDP and approximately 1% of US GDP. As part of the indirect (non-health-related) costs of smoking, the total productivity 
losses caused by smoking each year in the US have been estimated at US$151 billion.
2.  The costs of smoking notwithstanding, it produces some potential economic benefits. The economic activities generated from the production and con-
sumption of tobacco provides economic stimulus. It also produces huge tax revenues for most governments, especially in high-income countries, as well 
as employment in the tobacco industry. Income from the tobacco industry accounts for up to 7.4% of centrally collected government revenue in China. 
Smoking also yields cost savings in pension payments from the premature death of smokers.
3.  Smoking cessation measures could range from pharmacological treatment interventions to policy-based measures, community-based interventions, 
telecoms, media, and technology (TMT)-based interventions, school-based interventions, and workplace interventions.
4.  The cost per life year saved from the use of pharmacological treatment interventions ranged between US$128 and US$1,450 and up to US$4,400 per 
quality-adjusted life years (QALYs) saved. The use of pharmacotherapies such as varenicline, NRT, and Bupropion, when combined with GP counseling 
or other behavioral treatment interventions (such as proactive telephone counseling and Web-based delivery), is both clinically effective and cost effective 
to primary health care providers.
5.  Price-based policy measures such as increase in tobacco taxes are unarguably the most effective means of reducing the consumption of tobacco. A 10% 
tax-induced cigarette price increase anywhere in the world reduces smoking prevalence by between 4% and 8%. Net public benefits from tobacco tax, 
however, remain positive only when tax rates are between 42.9% and 91.1%. The cost effectiveness ratio of implementing non-price-based smoking 
cessation legislations (such as smoking restrictions in work places, public places, bans on tobacco advertisement, and raising the legal age of smokers) 
range from US$2 to US$112 per life year gained (LYG) while reducing smoking prevalence by up to 30%–82% in the long term (over a 50-year period).
6.  Smoking cessation classes are known to be most effective among community-based measures, as they could lead to a quit rate of up to 35%, but they usu-
ally incur higher costs than other measures such as self-help quit-smoking kits. On average, community pharmacist-based smoking cessation programs 
yield cost savings to the health system of between US$500 and US$614 per LYG.
7.  Advertising media, telecommunications, and other technology-based interventions (such as TV, radio, print, telephone, the Internet, PC, and other elec-
tronic media) usually have positive synergistic effects in reducing smoking prevalence especially when combined to deliver smoking cessation messages 
and counseling support. However, the outcomes on the cost effectiveness of TMT-based measures have been inconsistent, and this made it difficult to 
attribute results to specific media. The differences in reported cost effectiveness may be partly attributed to varying methodological approaches includ-
ing varying parametric inputs, differences in national contexts, differences in advertising campaigns tested on different media, and disparate levels of 
resourcing between campaigns. Due to its universal reach and low implementation costs, online campaign appears to be substantially more cost effective 
than other media, though it may not be as effective in reducing smoking prevalence.
8.  School-based smoking prevalence programs tend to reduce short-term smoking prevalence by between 30% and 70%. Total intervention costs could 
range from US$16,400 to US$580,000 depending on the scale and scope of intervention. The cost effectiveness of school-based programs show that one 
could expect a saving of approximately between US$2,000 and US$20,000 per QALY saved due to averted smoking after 2–4 years of follow-up.
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9.  Workplace-based interventions could represent a sound economic investment to both employers and the society at large, achieving a benefit–cost ratio of 
up to 8.75 and generating 12-month employer cost savings of between $150 and $540 per nonsmoking employee. Implementing smoke-free workplaces 
would also produce myriads of new quitters and reduce the amount of cigarette consumption, leading to cost savings in direct medical costs to primary 
health care providers. Workplace interventions are, however, likely to yield far greater economic benefits over the long term, as reduced prevalence will 
lead to a healthier and more productive workforce.
CONCLUSIONS: We conclude that the direct costs and externalities to society of smoking far outweigh any benefits that might be accruable at least 
when considered from the perspective of socially desirable outcomes (ie, in terms of a healthy population and a productive workforce). There are enormous 
differences in the application and economic measurement of smoking cessation measures across various types of interventions, methodologies, countries, 
economic settings, and health care systems, and these may have affected the comparability of the results of the studies reviewed. However, on the balance of 
probabilities, most of the cessation measures reviewed have not only proved effective but also cost effective in delivering the much desired cost savings and 
net gains to individuals and primary health care providers.
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Background
It is a known fact that both active and passive smoking are 
damaging to human health and have associated economic 
costs. Cigarette smoking is the cause of many preventable 
diseases,a leads to premature deaths, and accounts for a sig-
nificant proportion of many health inequalities. The World 
Health Organization (WHO) currently estimates that each 
year smoking accounts for about ~6 million deaths worldwide 
and causes about half a trillion dollars in economic damage 
annually.1 This number of smoking-attributable deaths is 
expected to rise to 7 million by 2020 and to more than 8 mil-
lion a year by 2030 if the current rate of smoking continues 
unabated.2 According to recent statistics from the Action on 
Smoking and Health,3 smoking causes ~80% of deaths from 
lung cancer, ~80% of deaths from bronchitis and emphysema, 
and ~17% of deaths from heart disease. More than one quar-
ter of all cancer deaths can be attributed to smoking. These 
include cancer of the lung, mouth, lip, throat, bladder, kid-
ney, pancreas, stomach, liver, and cervix. It is also estimated 
that globally 600,000 deaths a year are caused by second-hand 
smoke, and most of these deaths occur among women and 
children.
The US center for Disease Control and Prevention also 
reported that cigarette smoking is the proximate cause of 
over 440,000 premature deaths annually, of which 50,000 is 
attributable to second-hand smoke.4–6 Recent statistics from 
a  Cigarette smoking is a major contributor to chronic obstructive pulmonary disease, 
peripheral and cerebrovasular disease, coronary artery disease (CAD), cancer of the 
lung or pharynx, larynx, oesophagus, pancreas, bladder, kidney and cervix, peptic ulcer 
disease, and nonmalignant diseases of the mouth,134,135 among other smoking-induced 
illnesses.
the British National Health Service (NHS) Health and Social 
Care Information Centre7 shows that smoking accounts for 
about 100,000 deaths a year in the UK (79,100 in England, 
13,000 in Scotland, 5,600 in Wales, and 2,300 in Northern 
Ireland). This compares with similar studies for UK in 2009, 
which showed that there were 109,164 deaths due to smok-
ing (19% of all deaths in the UK), of which 27% deaths in 
men and 11% deaths in women can be traced to smoking.8 
These figures no doubt show that addiction to cigarette smok-
ing poses a lot of health risk and could be loosely described 
as a death sentence in disguise. Reducing the prevalence of this 
menace is thus a worthy cause for health care professionals, 
the government, and society at large.
This paper reviews the major studies on the econom-
ics of tobacco smoking and the economic impact of reducing 
its prevalence. The paper examines the following research 
questions:
1. What are the economic costs and benefits of smoking?
2. How effective and cost effective are smoking cessation 
measures in terms of delivering cost savings and net gains 
to individuals and primary health care providers?
The economic impact of smoking is twofold: the costs 
of tobacco use itself, and the costs of reducing its preva-
lence among smokers. Beyond the face value of cigarette 
purchases, the costs of tobacco use have more far-reaching 
health and economic implications on private individuals, 
families, employers, and taxpayers. The costs of smoking 
have thus been classified as direct, indirect, and intangible. 
The direct costs of smoking include the cost of illness due 
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to smoking on affected patients, and the health care expen-
diture involved in the treatment of smoking-related illnesses 
(eg, cost of drugs and administrative services). In the UK, 
direct costs of smoking arise from GP consultations, prescrip-
tions for drugs, and various costs related to treating diseases 
attributable to smoking.7 Direct costs could also include the 
resources used up by other agencies and charitable organi-
zations.9 The World Bank estimates that about 15% of the 
aggregate health care expenditure in high-income countries 
can be attributed to smoking.10,11 In the UK, the direct costs 
of smoking to the NHS have been estimated at between £2.7 
billion and £5.2 billion, which is equivalent to around 5% of 
the total NHS budget each year.3,7,8,12–14 Smoking also poses 
considerable indirect costs to society and the nonsmoking 
public, eg, costs of second-hand smoking, costs to employ-
ers in the form of loss of productivity and absenteeism of 
smokers owing to smoking-related illnesses.15 In addition, 
smoking-induced fires, sickness/invalidity benefits, litter, etc 
are all negative externalities of smoking to society. The direct 
and indirect costs of smoking can be measuredb and hence are 
tangible costs, whereas there are some costs that cannot be 
easily quantified, such as loss of life, and the burden of pain 
and suffering caused by smoking-induced illness.16,17 These 
unquantifiable costs are often referred to as the intangible 
costs of smoking.
Just as there are costs emanating from smoking, there are 
also benefits associated with reducing the incidence or preva-
lence of smoking. Benefits here refer to the losses that could 
be avoided by the individuals who quit smoking, such as cost 
savings from smoking in terms of reduced morbidity and mor-
tality, reductions in the costs of illness, and the marginal risk 
of disease.18 Other benefits of reducing smoking prevalence 
are longevity and improvement in the quality of life of quit-
ters and passive smokers, improved workplace productivity, 
reduced costs of cleaning up the environment after smoking, 
reduction in fires caused by smoking, and the resulting dam-
age or destruction, as well as a healthier population, among 
other benefits. There is a growing body of literature suggest-
ing that smoking cessation interventions, coupled with regu-
lations and legislations, are effective ways to reduce smoking 
prevalence.16,17,19,20 Furthermore, there is evidence to suggest 
that smoking cessation interventions are among the most cost-
effective and economically reasonable ways of appropriating 
health care resources.5,9–11,21–27
This study attempts to review the existing evidence on 
the economic, health-related, and non-health-related impact 
of reducing smoking prevalence. First, we summarize the 
search methods and selection procedure used to conduct the 
systematic review, and then we examine the quality assessment 
method used in evaluating the study quality. The paper utilizes 
b  For example, evidence from Kahende et al5 show that in the US, the medical costs (part 
of direct costs) and productivity losses (part of indirect costs) caused by cigarette smok-
ing can be estimated to be worth US$193 billion annually.
two main approaches used by medical researchers for economic 
evaluationc: cost-effectiveness analysis (CEA) and cost–benefit 
analysis (CBA). These are discussed in detail in Section “Mea-
sures of Evaluating Economic Impact”. The aim of this paper is 
to identify evidence on the effectiveness and cost effectiveness 
of smoking cessation interventions and also to identify data 
that may be of use in the economic modeling of the cost savings 
and net benefits derivable from investing in smoking cessation 
programs in the UK. Two specific pieces of work are presented 
in this review. The Section “Global Evidence on the Economics 
of Smoking” examines the evidence globally on the costs and 
benefits attributable to smoking, and then reviews the literature 
on the effectiveness and cost effectiveness of smoking cessation 
programs across countries. These will be examined under six 
broad headings: 1) pharmacological treatment interventions, 
2) policy-based interventions, 3) community based interven-
tions, 4) telecoms, media, and technology (TMT)-based inter-
ventions, 5) school-based interventions, and 6) workplace- or 
employer-based interventions. The second major segment of 
this review (“The Economic Impact of Smoking and Smoking-
cessation Interventions in UK”) examines the economic impact 
of smoking in the UK. The rationale for narrowing down to UK 
is to assess how these various types of interventions are applied 
in a single country case study. Here, the costs and benefits 
of smoking in the UK are examined, as well as the effective-
ness and cost effectiveness of UK-specific smoking cessation 
intervention programs. The Section “Discussion” discusses the 
main findings of the review by comparing results across types 
of intervention, across countries, and across measurement out-
comes, and in some cases, providing the range of costs or cost 
savings for each intervention by combining costs from multiple 
sources. The section also discusses some of the known limita-
tions of the study.
Research Methods
Search methods and selection criteria: overview. 
A systematic review produced several studies, out of which 
a total of 99 literature sources on the economics of smoking 
and of reducing smoking prevalence were used for the review. 
We captured major economic studies on the health and eco-
nomic impact of smoking and cost effectiveness of tobacco 
policies published between 1992 and 2014, but included only 
eight relevant studies before 1992. We also performed hand-
searching of relevant articles, which produced additional 52 
papers, including useful non-economic studies, and health 
reports and white papers issued by government bodies, inter-
national health organizations and health intervention cam-
paign agencies that are usually not included in the electronic 
databases. This brings the total number of studies included 
in the review to 151. Of this number, 123 were strictly peer-
reviewed medical journals, while 28 were useful government 
c  Other approaches that are not considered in this analysis include Cost Analysis (CA) 
and Cost Utility Analysis (CUA)—see Kahende et al5).
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(public health) reports and white papers. This paper bene-
fits strongly from the inclusion and synthesis of high-level 
evidence from mostly recent studies (eg, 2005–2014), with 
the implication that newer and better methods, indicators, 
or measures have been reported in order to aid economic 
modeling.
Study outcomes. Primary outcomes of the selected studies 
are smoking prevalence, direct and indirect costs of smoking, 
and the costs and benefits of smoking cessation interventions 
(eg “cost per quitter”, “cost per quality of life year gained”, 
“cost per life saved”, “present value” or “net benefits” from 
smoking cessation, and “cost savings” from personal health 
care expenditure).
Identification of studies. Two main electronic databases 
were searched. These are PUBMED ( January 1992 to July 
2014) and CRD (NIHS) ( January 1992 to July 2014). The rea-
son for the selection of these databases is that they are both 
very comprehensive databases containing health care-related 
studies. For example, PUBMED contains more than 23 mil-
lion citations for biomedical literature from MEDLINE. The 
CRD database also contains the NHS Economic Evaluation 
Database, the Cochrane Library of Systematic Reviews in 
health care and health policy, and other health care-related bib-
liographic sources. To identify relevant studies for this review, 
we used a detailed search strategy for each database. These 
were based on the search strategy developed for PUBMED 
but revised appropriately for each database to take account of 
differences such as vocabulary and syntax rules. Key terms used 
were “economic” or “costs”, or “cost effectiveness” and “smok-
ing”, or “tobacco” for the international evidence section, while 
the search strategy for the UK segment of the study included 
“UK” to the list of key words (see Supplementary File 1). Other 
keywords used were “tobacco control”, “smoking reduction”, 
and “smoking cessation”. We also performed hand searches 
on other databases such as EconLit, Science Direct, JSTOR, 
Cochrane Library, and Google Scholar using the same key-
words, and this produced most of the papers already contained 
in PUBMED/MEDLINE and CRD. Unpublished reports, 
abstracts, brief and preliminary reports were considered for 
inclusion on the same basis as published reports. There was no 
restriction based on language or date.
Data collection and analysis. 
Selection of studies. The authors read all titles and/or 
abstracts resulting from the search process, and any irrelevant 
studies were removed. Full copies of the remaining potentially 
relevant studies were obtained and assessed independently by 
the authors to ensure that these clearly met all inclusion crite-
ria. Those that were clearly irrelevant or had insufficient infor-
mation to make a decision were excluded, or the authors were 
contacted for further information to aid the decision process. 
Decisions were based on inclusion criteria, ie, types of studies, 
types of participants, interventions, and outcome measures 
used. Variations in authors’ opinion were resolved through 
discussion and consensus.
Under the review of international (non-UK) evidence in 
Section “Global evidence on the economics of smoking”, we 
assessed and summarized 36 papers on the costs and benefits 
of smoking as well as 65 papers on the effectiveness and cost 
effectiveness of smoking cessation interventions across coun-
tries. Though a substantial part of the evidence on the eco-
nomics of smoking were drawn from the United States, we 
tried as much as possible to reflect pockets of evidence from 
other countries around the world, especially from China, the 
largest producer and consumer of tobacco products, as well as 
from Australia, Hong Kong, Korea, Thailand, Taiwan, Swe-
den, France, Belgium, Denmark, India, Turkey, Netherlands, 
and Canada.26,28–42 These countries appear to be known to 
have carried out comprehensive tobacco control policies. This 
study reviewed only relevant papers on the effectiveness and 
cost effectiveness of smoking cessation under six headings: 
pharmacological interventions (8), policy-based interventions 
(19), community-based interventions, (10), TMT-based inter-
ventions (12), school-based interventions (5) and workplace- or 
employer-based interventions (7).
With regard to the UK, in Section “The economic impact 
of smoking and smoking cessation interventions in UK”, this 
study reviewed 33 papers, 19 on the costs and benefits of 
smoking in UK and 14 studies on the effectiveness and cost 
effectiveness of UK-specific smoking cessation interventions. 
Cost estimates are mostly expressed in US dollars for interna-
tional evidence (except where stated otherwise) and in British 
pounds for UK evidence.
Data extraction and management. Data were extracted 
from published sources using a standard data recording form. 
Studies that reported primary outcomes were extracted and 
reviewed. At the first level of screening, we excluded papers 
that merely described the effectiveness of an intervention 
without including economic or cost considerations. We also 
excluded studies that combined smoking cessation with the 
reduction in the risk of other diseases such as lung can-
cer, myocardial infarction, chronic obstructive pulmonary 
disease (COPD), stroke, obesity, diabetes, coronary heart 
disease, etc. At the second level of screening, we excluded 
papers in which study design, methods, or outcomes did not 
appear to be consistent with those of the review as well as 
publications that appeared more than once in both databases. 
Figure 1 illustrates the study selection process more clearly.
Risk of bias. The risk of bias in studies was assessed via 
the criteria described in version 5.0.0 of Cochrane Review-
ers Handbook.43 This is based on the evaluation of six specific 
methodological domains (ie, sequence generation, alloca-
tion concealment, blinding, incomplete outcome data, selec-
tive outcome reporting, and other issues). Generally, the six 
domains are used by answering a prespecified question about 
the adequacy of each study in relation to each domain, such 
that a judgment of “Yes” indicates low risk of bias, “No” indi-
cates high risk of bias, and “Unclear” indicates unclear or 
unknown risk of bias.
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Figure 1. Flowchart of study selection process.
For this review, the following domains were used: seq-
uence generation, allocation concealment (avoidance of selec-
tion bias), incomplete outcome data, and selective outcome 
reporting. Blinding was not possible because of the nature of 
some of the studies/intervention used.
Measures of evaluating economic impact. We now dis-
cuss two methods commonly used by medical researchers for 
economic evaluation: cost effective analysis (CEA) and cost-
benefit analysis (CBA).
Cost effectiveness analysis. CEA is a measure of cost sav-
ings. It tends to link the cost of an intervention to the health 
improvements or gains caused by that intervention. Measures 
of health improvements include cases avoided (CA), hospi-
tal days avoided (HDA), deaths averted (DA), and life-years 
saved (LYS).5 Other measures include cost per quitter (CPQ ) 
enrolled in community-based cessation programs such as a 
self-help program, a smoking cessation class, an incentive-
based cessation contest,44 or in a quitline program.45 The cost 
effectiveness of a cessation program may not only be looked at 
in absolute terms but also in relative or comparative terms to 
other intervention programs because each program may have 
different dimensions of cost effectiveness. Cost effectiveness 
is usually measured in ratios. A higher cost effectiveness ratio 
means that a program is less cost effective than another inter-
vention program. However, Altman et al44 put forward an 
argument that the fact that an intervention program yields a 
high cost effectiveness ratio does not necessarily imply that 
it is a less desirable outcome. It may well mean that even the 
most cost-effective program only impacts on a small fraction 
of the population in need, so that a wiser decision would be 
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to implement as many cost-effective programs that satisfy the 
needs of more diverse groups of citizens.
Cost–benefit analysis. CBA is an economic technique 
that is used in evaluating the economic soundness or feasi-
bility of an intervention program. CBA measures both the 
costs and monetary benefits derivable from an intervention, 
discounted at their present value. Discounting helps to make 
divergent outcomes of costs and benefits comparable irrespec-
tive of the date at which they occur. According to Phillips 
and Prowle,22 there are three basic stages involved when 
conducting a CBA: (1) the costs incurred in the interven-
tion program must be identified, measured, and assessed; 
(2) the benefits associated with the intervention also has to be 
identified, measured, and assessed in which case any input–
output misalignments or time-dependent outcomes (eg, of 
a reduction in smoking prevalence) will have to be adjusted; 
(3) the costs and adjusted benefits are now combined to arrive 
at a measure of the net present value of outcomes, ie, the dif-
ference between the present value of benefits and the present 
value of costs. If benefits exceed costs, then the intervention is 
economically viable, and has a positive net benefit. Otherwise, 
it has a negative net benefit. Another way of looking at this is 
to estimate the benefit–cost ratio, that is, the present value of 
benefits divided by the present value of costs. The higher the 
benefit–cost ratio, the more desirable is the outcome of the 
intervention. It should be noted that many health researchers 
find it difficult to attach monetary values to health outcomes, 
and hence find the technique less useful than CEA and CUA.5
Global Evidence on the Economics of Smoking
According to the Campaign for Tobacco-Free Kids,46 the top 
five cigarette-consuming countries are China, Russia, United 
States, Japan, and Indonesia. China consumes more than 35% of 
the world’s cigarettes, with 53% of males  smoking. Philip  Morris 
International, British American Tobacco, Japan Toba cco Interna-
tional, and Imperial Tobacco are the world’s four largest multina-
tional tobacco companies. The largest state tobacco monopoly is 
the China National Tobacco Corporation, which has the largest 
share of the global market among all companies. Based on WHO 
estimates, tobacco use costs the world an estimated $500 billion 
each year in health care expenditures, productivity losses, fire 
damage, and other costs. In the US alone, smoking causes more 
than $193 billion each year in health-related costs, including 
medical costs and the cost of lost produc tivity caused by smok-
ing.5,47 New figures from the Campaign for Tobacco-Free Kids 
show that the social cost of smoking in the US could be estimated 
at about US$321 billion (ie both smoking-caused health costs 
of US$170 billion and associated productivity losses of US$151 
billion).59 (See  Fig. 2). This section examines the economic costs 
and benefits of smoking in some detail, citing examples from 
countries where tobacco is in high demand and use.
Smoking-attributable costs and benefits. As shown 
earlier, the costs of smoking can be classified into health-
related costs and non-health-related costs.
Health-related costs. The health care costs associated 
with tobacco-related illnesses are extremely high. In the 
United States, total annual public and private health care expe-
nditures caused by smoking amount to approximately US$170 
billion.59 Measured as a proportion of the gross domestic prod-
uct (GDP), smoking costs in the US are approximately 1% of the 
GDP. Many studies have estimated the health-related costs of 
smoking. These costs include medical expenditure on drugs and 
administration, smoking-attributable morbidity and mortality, 
medical costs attributable to passive smoking, maternal smok-
ing, and children smoking. Other direct costs include sickness/
invalidity benefits attributable to tobacco abuse. A study by 
Yang et al48 reveals three ways in which smoking-attributable 
expenditures could be measured—average expenditure per in-
patient hospitalization (or admission), average expenditure per 
outpatient visit, and self-medication expenditures. Some other 
indicators of health care expenditure include smoking-induced 
emergency and general practitioner visits for adults and chil-
dren, and use of nursing homes and home-based care.49
Annual federal and state government smoking-caused 
Medicaid payments are estimated at US$39.6 billion (federal 
share: US$22.5 billion; states’ share: US$17.1 billion) (see Fig. 2). 
State-level estimates from USA revealed that the direct costs 
of smoking in California in 1999 were US$8.6 billion, with 
nearly half of this amount (47%) going to hospital care, 24% 
for ambulatory care, 15% for nursing home care, 13% for pre-
scriptions, and 1% for domestic health care services.4 Fresh 
statistics from Campaign for Tobacco-Free Kids50 on state 
tobacco-related costs and revenues has revealed that smoking-
related medical expenditures in US varied dramatically across 
states, with a low of US$22.4 million in Wyoming to a high 
of US$3.31 billion in New York. Another report by Armour 
et al51 showed that the proportion of health care expenditure 
attributable to smoking ranged between 6% and 18% across 
the different states.
The National Drug Strategy in Australia estimated the 
total social costs of smoking in Australia between 2004 and 
2005 at about AUD$31.4 billion, representing 56.2% of total 
costs of drug abuse in Australia.16 Of these costs, AUD$12.02 
billion or 38.2% was classified as tangible costs, while 
AUD$19.45 billion or 61.8% was intangible costs. Yang et al48 
estimated the economic burden of smoking for 2008 in China 
at US$28.9 billion, representing 0.7% of China’s GDP and 3% 
of national health care expenditures. This figure also averaged 
US$127.30 per smoker. According to the study, mortality costs 
contributed the most to smoking-attributable costs in China, 
followed by outpatient expenditures. Results also show that, 
as a result of high prevalence rate, a whopping 93% of total 
economic cost of smoking in China was borne by men. Results 
from Hong Kong reveal that annual health-related cost of 
smoking in 1998 was US$688 million.49 The same study shows 
that about 5,596 deaths in Hong Kong among adults 35 years 
of age and above in 1998 was attributable to active smoking, 
while passive smoking accounted for 1,324 deaths. This brings 
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to a total of 6,920 tobacco-related deaths out of 32,847 deaths. 
In what seems very surprising, passive smoking accounted for 
23% of total smoking-related health care costs in Hong Kong, 
implying a growing risk of the prevalence of passive smok-
ing. In Taiwan, the total smoking-attributable expenditures 
(SAEs) totaled US$397.6 million, representing 6.8% of the 
total medical expenditures for people aged 35 years and over.52 
The mean annual medical expenditure per smoker was US$70 
more than that of each nonsmoker.
Although the health risks associated with passive 
smokingd have been well documented in the literature, lit-
tle is known about the economic costs. Regular exposure 
to second-hand smoke (SHS) among nonsmokers both at 
home and in the workplace could be economically costly 
in as much as it poses enormous health hazards. Follow-
ing a recent research conducted by Plescia et al53 on SHS 
exposure in North Carolina, the total annual cost of treat-
ment for conditions related to such exposure was estimated 
to be US$293.3 million in 2009. Though the majority of 
the SHS victims were children, the most common cases 
were traceable to cardiovascular conditions. In a similar 
study in Minnesota by Waters et al,54 the total annual cost 
of treatment for conditions associated with SHS was esti-
mated to be US$228.7 million in 2008 dollars—equivalent 
to US$44.58 per Minnesota resident. Just as passive smok-
ing poses huge health care costs, smoking during preg-
nancy, otherwise called “maternal smoking”, also has some 
related cost implications. It is associated with considerably 
higher child health expenditures as well as increase in overall 
d  Passive smoking has some causal relationships with coronary heart disease, heart 
attacks, and chronic respiratory symptoms. For children and infants, SHS exposure 
can also lead to low birth weight, sudden infant death syndrome (SIDS), childhood 
respiratory illness and Asthma, amongst others. In US, about 53,000 deaths of non-
smokers can be attributed to passive smoking (56:s39).
medical costs.55 For example, the annual direct medical 
expenditure for early childhood respiratory illness attrib-
utable to maternal smoking totaled US$661 million for all 
children under the age of six.56 Further evidence reveals 
that smoking-attributable neonatal costs in the US repre-
sent almost US$367 million in 1996 dollars.57 Though these 
costs vary considerably from state to state, they can easily 
be avoided by implementing temporary cessation programs 
aimed at pregnant women.
The foregoing statistics indicate that smoking everywhere 
is very costly in many respects and takes a huge toll on public 
finances. For most countries, smoking-attributable costs rep-
resent the largest single expenditure in total health care costs, 
with wider implications for the economy.
Non-health-related costs. Besides the health care costs 
of smoking, there are other costs that the abuse of tobacco 
imposes on society, and these costs need not be treated as less 
important. Tobacco-related illnesses and premature mortality 
impose high productivity costs to the economy because of sick 
workers and those who die prematurely during their working 
years. Lost economic opportunities in highly populated devel-
oping countries are likely to be particularly severe as tobacco 
use is high and growing in those areas.58 Countries that are 
net importers of tobacco leaf and tobacco products lose mil-
lions of dollars a year in foreign exchanges. Fire damage and 
the related costs are significant. In 2000, about 300,000 or 
10% of all fire deaths worldwide were caused by smoking, 
and the estimated total cost of fires caused by smoking was 
US$27 billion.59 Tobacco production and use also damage the 
environment and divert agricultural land that could be used 
to grow food.
The economic loss to employers in the form of work-
place absenteeism and the resulting lost productivity of their 
smoking employees is particularly alarming. In specific terms, 
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Figure 2. smoking-attributable expenditure in the United states (UsD billion).
Note: campaign for Tobacco-Free Kids.50
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employers suffer loss of revenue from the days off work and 
earnings lost from work owing to smoking-induced illness 
and premature death of its smoking employees during pro-
ductive years. It is reported that US smokers are absent from 
work approximately 6.5 days more per year than nonsmokers. 
They make about six visits more to the health care centers per 
year than their nonsmoking counterparts, while dependents 
of smokers visit health care centers four times more than non-
smokers.23,56 Recent US statistics show that the total cost of 
productivity losses caused by smoking each year amounts to 
US$151 billion.47,59 This estimate only includes costs from 
productive work lives shortened by smoking-caused death, and 
does not include costs from smoking-caused disability during 
work lives, smoking-caused sick days, or smoking-caused pro-
ductivity declines when at work, all of which amount to huge 
economic losses to the US. In California alone, the annual 
value of lost productivity owing to smoking-related illness 
between 2000 and 2004 averaged US$8.54 billion (US$6.87 
billion for Florida; US$6.79 billion for Texas, and US$6.05 
billion for New York), showing that these US states and many 
others have lost huge productive hours and potential revenue 
owing to smoking-induced health problems. These results 
suggest that, if adequate measures are taken by primary health 
authorities and employers to promote smoking cessation, there 
will be huge cost savings from smoking-related illnesses and 
premature deaths.
Absenteeism and premature deaths represent only a frac-
tion of the aggregate indirect burden of smoking to employers. 
It may well be that even at work smoking-induced illness could 
retard the performance of smoking employees and translate 
into lost time and earnings, which may not be easily quan-
tified. Arguing in this light, Thompson and Forbes60 noted 
that productivity losses emanating from smoking for the most 
part arise from short-term absenteeism or from performance 
at less than full efficiency due to respiratory problems or other 
smoking-induced illnesses. However, one cannot overlook 
the impact of other qualitative factors that lead to absentee-
ism and reduced productivity such as other health indicators 
(alcohol, weight, exercise, etc), job characteristics (occupation 
type, income, employment status, hours worked), and demo-
graphic characteristics (age, sex, ethnicity, marital status, edu-
cation, place of work, etc). Evidence from Bush and Wooden61 
revealed that, even after controlling for these factors, smok-
ing was still highly correlated with work-place absenteeism. 
In fact, in their 1994 paper on the impact of smoking and 
alcohol on workplace absence, Bush and Wooden concluded 
that, after controlling for the effect of other variables, employ-
ees on smoking status were found to be 1.4 times more likely 
to be absent, and ex-smokers were found to be 1.3 times more 
likely to be absent than nonsmokers. Their results also showed 
that the probabilities of smoking-induced absenteeism dif-
fered considerably by sex. For male smokers, the probability 
of workplace absence surpassed that of male non-smokers by 
1.7 times, while for female smokers the probability of absence 
fell slightly to 1.2 times more than those females who have 
never smoked.
Apart from smoking-attributable absenteeism, cigarette 
smoking and its associated activities can also be economically 
costly when they are the cause of fires. In the study conducted 
by Collins and Lapsley,17 the total cost of smoking-attributable 
fires in New South Wales, Australia, in 2006/2007 was esti-
mated at AUD$51.4 million, with tangible costs representing 
over three-quarters of the total cost. In USA, smoking-induced 
fires lead to the death of 2,300 civilians (men, women, and 
children inclusive) per year, with additional 5,000 injuries per 
year.23,56 Besides the health care costs of treating injured or 
burn victims, direct property damaged from fires induced by 
tobacco has been valued at US$552 million per year. Other 
costs to employers of workers who smoke include health care 
claims and benefits not related to health care.23 There are also 
some hidden costs that are economically significant to society 
but often omitted in most studies for the lack of satisfactory 
data, eg, costs of paramedical and ambulance services, dam-
age caused by smoking-induced forest fires, toxic effects from 
tobacco consumption, especially amongst children, as well as 
accidents and other property loss caused by cigarette smoking 
apart from fires.
Economic benefits of smoking. The cost of smoking not-
withstanding, the tobacco industry poses a great deal of ben-
efits, especially to the economy, consumers, and producers. 
It is therefore imperative to examine the positive economic 
effects of smoking and, hence, the impact or consequences 
on these of reducing smoking prevalence. Following previous 
studies by Thompson and Forbes,60 Woodfield,62 and Cohen 
and Barton,56 among others, the major benefits of smoking are 
in economic stimulation, namely income generated from pro-
duction and consumption, tax yields, employment, and early 
death of smokers. Taxes on cigarettes have always contributed 
to government treasury. In 2009, President Barrack Obama 
signed an act that raised the US federal tax rate on cigarettes 
from 39 cents to US$1.01 per pack. The 156% tax increase was 
estimated to earn the US government about US$33 billion in 
tax over a 4½-year period. There are, however, economic con-
sequences of raising taxes (see “The economics of policy-based 
interventions” Section).
The World Bank estimates that tobacco farming employs 
about 33 million people worldwide, and about 15 million of 
those workers reside in China alone.63 In China, over 4 mil-
lion households rely on tobacco for their livelihood, as tobacco 
farmers, cigarette industry retailers, or employees.32 In fact, 
China is the largest producer and consumer of tobacco world-
wide. All cigarettes are produced by the Chinese govern-
ment’s tobacco monopoly company, which produces more than 
1.7 trillion cigarettes annually. In 2003, the company gener-
ated almost US$2 billion in profits and taxes, while income 
from tobacco represented about 7.4% of centrally collected 
government revenue. In terms of consumption, China boasts 
of a smoking population of 350 million active smokers and 
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of cessation interventions, two major indicators are necessary: 
the number of long-term quitters and the health gains from 
smoking cessation, measured according to the age and sex of 
the quitters.19 In estimating the cost effectiveness of smoking 
cessation interventions, emphasis is placed on the impact of 
such interventions on direct cost reductions with respect to 
smoking-related morbidity and mortality rates as well as the 
effect on long-term medical expenditure.
Pharmacological treatment interventions. There are sev-
eral pharmacological agents that are commonly used to aid 
smokers in their quest to quit smoking. However, we will 
concentrate on the three major types: nicotine replacement 
therapy (NRT), bupropion sustained release (SR), and vareni-
cline. These treatment interventions are widely available on 
prescription, and in the case of NRT as an over-the-counter 
medication. They are licensed as first-line treatments for use as 
smoking-cessation aids in the US and the EU, and are widely 
recommended in many national guidelines.64
The aim of NRT is to temporarily replace much of the 
nicotine from cigarettes to reduce motivation to smoke and 
the physiological and psychological withdrawal symptoms 
often experienced during a quit attempt, thus easing the 
transition from cigarette smoking to complete abstinence. It 
is available in various forms and dosages, including transder-
mal patches (ie, absorbed slowly through the skin), as chew-
ing gum, oral and nasal sprays, lozenges, sublingual tablets, 
and inhalers. NRT, in all its commercially available forms, 
has been found to help people who make a quit attempt to 
increase their chances of successfully stopping smoking. NRT 
increase the rate of quitting by as much as 50%–70% regard-
less of setting.65
Bupropion was developed as a non-tricyclic antidepres-
sant, and is sometimes preferred by smokers who do not wish 
to use a nicotine-based treatment, or who have already failed 
to quit using NRT. The usual dose for smoking cessation is 
150 mg once a day for 3 days, increasing to 150 mg twice a 
day, continued for 7–12 weeks.64 The quit attempt is generally 
initiated a week after starting pharmacotherapy. Some studies 
have shown that bupropion doses up to 300 mg per day does 
have significant effect in a dose–response fashion on smok-
ing cessation, but does not seem to affect long-term cessation 
rates (see66).
Varenicline is a selective nicotinic receptor partial 
agonist, licensed as a prescription-only treatment for smoking 
cessation in USA in 2006 and in Europe in 2006/2007. The 
standard regimen is 1 mg twice a day for 12 weeks, with the 
first week titrated to reduce side effects, and quit date set for 
the second week. Varenicline has helped ~50% more people 
to quit than nicotine patch and “other” NRT (tablets, sprays, 
lozenges, and inhalers) and ~70% more people than nicotine 
gum.64 This means that for every 10 people who quit with 
NRT patch or with “other” NRT, about 15 could be expected 
to quit with varenicline, and for every 10 who quit with NRT 
gum, about 17 could be expected to quit with varenicline.
460 million passive smokers. In 2010, about 52.9% of Chinese 
men and 2.4% of women were current smokers.48 Given that 
China is the most populous country in the world, this propor-
tion of smokers translates into enormous earning potential.
Apart from the income benefits of tobacco smoking, 
another source of benefit, especially to the government, of 
smoking is the substantial cost savings in pension payments 
from premature death of smokers. This is a highly debated issue 
in the literature, because it is premised on the thinking that a 
shorter life expectancy implies a reduced expenditure on pen-
sions. Thus, attempts to promote this will be deemed socially 
undesirable and hence cannot be incorporated into social pol-
icy design.60,62
Clearly, from the above, therefore, if tobacco farming is to 
be phased out, many households, investors, and the government 
itself will suffer huge economic losses. Hence there is a need to 
strike a balance between the costs and benefits of smoking. But 
this is easier said than done, especially as the health implica-
tions of smoking far outweigh any associated economic returns 
from the perspective of a socially desirable outcome.
Effectiveness and cost effectiveness of smoking cessa-
tion interventions. Because the health hazards attributable to 
smoking are very significant, the risks of illness or disease are 
reduced following smoking-cessation interventions.19 Accord-
ing to a UK General Household Survey in 1998, about 27% 
of adults (aged 16 years and above) were smokers, and of this 
figure about 70% wanted to quit smoking. Data from a sim-
ilar survey conducted in 1994 by the US health authorities 
indicated that 46.4% of smokers had made serious attempts to 
stop in the year preceding the survey, but only 5.7% of smokers 
managed to abstain from smoking after a period of 1 month 
or more, and only 2.5% of smokers are able to achieve perma-
nent abstinence each year. The reason for this is smoking is an 
addiction and can hardly be stopped on the basis of will power 
alone. Evidence from Feenstra et al11 shows that only ~3%–7% 
of smokers who attempt to stop smoking on will power are 
still abstinent after 1 year. In order to enhance quit rates, there 
must be some deliberate measures to incentivize cessation. 
There are different forms of smoking cessation interventions, 
and they range from pharmacological treatment interventions 
to policy-based interventions, community-based cessation 
programs, TMT-based interventions, school-based interven-
tions, and workplace- or employer-based interventions.
The aim of this section is to identify and evaluate cross-
country evidence on the effectiveness and cost effectiveness 
of smoking cessation interventions. The idea of carrying out 
economic evaluations is to identify which interventions uti-
lize the least resources or have greater cost savings, while 
being most effective in reducing both the number of smokers 
and the health- and non-health-related risks associated with 
smoking. By comparing the costs and outcomes of different 
alternative interventions, economic evaluations help health 
care professionals and policy makers in deciding the most effi-
cient use of scarce resources.24 In estimating the effectiveness 
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NRT, bupropion, and varenicline all improve the chances 
of quitting, with low risk of harms, and in some cases, using 
a combination of these pharmacological treatments could be 
seen to be even more clinically effective. However, as noted 
earlier, to justify the investment in any intervention, its effec-
tiveness must be evaluated alongside its cost effectiveness. The 
cost effectiveness of pharmacological interventions is thus as 
important as their clinical effectiveness. A review of economic 
studies on these pharmacological treatment interventions (see 
Supplementary File 2) showed that varenicline and bupropion 
(with or without behavioral interventions) are more cost effec-
tive than NRT measures such as nicotine gum, patch, lozenge, 
and inhaler. A recent study by the Canadian Agency for Drugs 
and Technologies33 found that, if providers’ willingness to pay 
(WTP) was greater than US$10,000 per QALY gained, then 
varenicline was the optimal treatment of choice compared to 
NRT and bupropion.
Several studies have also found that the use of NRT and/
or bupropion SR along with GP counseling is both clinical and 
cost effective in primary health care. For example, Stapleton 
et al67 showed that contingent prescriptions could yield addi-
tional life years at a cost between £398 (US$724) and £758 
(US$1,380) in 1998 UK pounds compared to brief counsel-
ing alone. In a similar estimation of the cost effectiveness of 
treating nicotine dependence (including NRT and counsel-
ing), Croghan et al68 found the aggregate 1-year smoking rate 
to be 22% with a cost of $9,231 per net life year gained. This 
cost compares favorably with other medical services that rely 
only on GP counseling however brief or intensive. Although 
NRT products can be purchased over the counter, many peo-
ple have suggested that free NRT treatments yield more posi-
tive results in terms of number of quitters than other cessation 
interventions. For example, Ong and Glantz69 found that in 
Minnesota, a free NRT program would generate 18,500 quit-
ters at a cost of US$4,440 per quality of life adjusted years 
(QALY) compared to implementing a smoke-free workplace 
policy, which would generate 10,400 quitters at US$506 
per QALY.
Nielsen and Fiore70 conducted a CBA of bupropion SR 
and nicotine transdermal patch (NTP) to see which of the 
two, or whether a combination of both, was more cost effective 
for smoking cessation. The results revealed that bupropion is 
more cost beneficial than either NTP or bupropion and NTP 
together, producing a net benefit in the first post-quit year of 
up to £338 per employee who attempts to quit compared with 
US $26 for NTP only, US$178 for the two combined, and 
US$258 for placebo, another pharmaceutical therapeutic that 
was used in the clinical trials. Thus, according to this study, 
bupropion is able to offer the most substantial monetary bene-
fits than any other pharmacological treatment. In a more recent 
study by Bolin et al,31 the cost effectiveness of varenicline was 
compared with nicotine patches for smoking cessation in four 
European countries (Belgium, France, Sweden, and UK). 
Surprisingly, the results showed that the use of varenicline 
for smoking cessation was associated with reduced smoking-
related morbidity and mortality more than was the case using 
NRT. The number of morbidities avoided per 1,000 smokers 
who made attempts to quit ranged from 9.7 in Belgium to 6.5 
in UK. The number of QALY gained, per 1000 smokers, was 
23 in Belgium, 19.5 in France, 29.9 in Sweden, and 23.7 in UK. 
The results of the base-case simulations revealed that, with the 
exception of France, varenicline treatment appeared to be more 
cost effective and cost saving than NRT. Thus, funding vareni-
cline as a smoking cessation aid is an economically justifiable 
use of health care resources in these countries.
The economics of policy-based interventions. This subsection 
takes a look at the global evidence on the economic conse-
quences of policy-based measures that aid smoking cessation. 
These include price-based measures (eg, increase in tobacco 
taxes, limitations on tobacco crop subsidies) and non-price 
measures (eg, no smoking regulations at work and in public 
places, restriction on sales to minors, and bans on promotion 
and advertising, etc). Legislative bans could either ban smok-
ing completely (comprehensive) or restrict it to designated 
areas (partial). Both price-based measures and legislation-
based smoking bans or restrictions have been found to yield 
both health and economic gains, including (1) reduction in 
smoking prevalence though reductions in the demand for and 
consumption of cigarettes, (2) significant reductions in the 
incidence of smoking-related diseases and deaths, (3) reduc-
tion in smoking-related medical costs, and (4) large gains in 
cumulative life years and QALYs.23,36,37,71–79
Increase in tobacco taxes. The most widely used measure to 
reduce the demand for tobacco is increase in taxes. This puts an 
upward pressure on tobacco prices, and higher tobacco prices 
tend to significantly reduce the consumption of tobacco.74,77 
According to a World Bank report,63 when taxes are raised on 
tobacco, consumption decreases especially in young people; a 
10% cigarette price increase results in a 7% decrease in smoking 
by young people and 4% by the general public. It has also been 
hypothesized that a price increase of 10% would reduce smok-
ing by 4% in high-income countries and by about 8% in low-and 
middle-income countries.23,71 In other words, the price elastic-
ity of demand for tobacco is higher in low- and middle-income 
countries and among populations of young or teenage smokers 
who are the most responsive to price changes. Smokers in high-
income countries are, however, less responsive to price changes. 
According to Atkinson and Townsend,80 low price sensitivity 
means that the revenue argument against tax increases is rather 
unconvincing. As long as prices do not respond proportionately 
to tax increases (ie, price elasticity of less than 1), the revenue 
from tobacco will surely increase when taxes go up since “a fall 
in consumption is more than offset by the extra tax paid by those 
who continue to smoke” (pp. 492). Thus, according to Atkinson 
and Townsend, so long as the reduction in tobacco consump-
tion is attributable to increased duty, the amount of corporate 
revenue from tobacco is likely to remain unaffected. The World 
Bank has recommended that “Governments increase tobacco 
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tax to about 65% of retail price”.63 Increasing tobacco prices also 
increases the chances of cigarette theft, smuggling, and coun-
terfeiting. The Mackinac Center on Public Policy estimates 
that profits made illegally from smuggling cigarettes to the 
US could amount to be between US$10 billion and US$17 bil-
lion.81 Over the years, tobacco tax increases have brought about 
increases in revenue for the government, even when the inci-
dence of smuggling and tax evasion are discounted. Currently, 
in most high-income countries where tobacco control policies 
are very comprehensive, tobacco taxes represent between two-
thirds and four-fifths of the retail price of cigarettes, whereas 
in low- and middle-income countries, they are generally below 
50% of the total price.
Apart from the decline in tobacco consumption via 
increased prices, raising cigarette taxes also poses some potential 
health and cost-saving benefits. Reduced tobacco consumption 
leads to a reduction in health care costs as former smokers and 
their children do not require as much medical care or treat-
ment as they used to.23 There is also another argument that says 
that huge tobacco taxes are equitable in the sense that it makes 
the tobacco industry pay more for the huge economic burden 
placed by its products to the health care system as well as the 
negative externalities of same to society. The income generated 
from tobacco taxes can also be used to finance community edu-
cation and advertising against tobacco. In China, the largest 
producer and consumer of tobacco, a recent tobacco tax adjust-
ment has just been implemented and, if this tax increase passes 
through to retail prices, it is expected to reduce the number of 
smokers by 630,000 saving 210,000 lives, at a price elasticity of 
-0.15.32 Following the same model, a tax increase of 1RMB (or 
US$0.13) per pack of cigarettes is expected to increase the rev-
enue accruable to the Chinese government by 129 billion RMB 
(US$17.2 billion), reduce consumption by 3.0 billion packs of 
cigarettes, reduce the number of smokers by 3.42 million, and 
save 1.14 million lives. These figures indicate that tobacco tax 
increase in China can be construed as the most cost-effective 
measure of smoking cessation.
In summary, tobacco tax increases reduces tobacco con-
sumption via higher cigarette prices, raises government rev-
enue, saves more lives, preserves employment, and reduces 
tobacco farming. However, whether or not tax increases lead 
to loss of revenue in the tobacco industry is still a subject of 
debate, as smuggling and tax evasion help to minimize any 
losses arising from taxation.
Smoking restrictions in the work place and in public places. 
It is in recognition of the dangers of passive smoking that 
many governments institute no smoking restrictions in pub-
lic places (eg, bars, restaurants, public buses, trains, airports, 
government buildings, and other public facilities) and private 
workplaces. Governments are now increasingly sensitive to 
the need to protect its citizens from the externalities caused 
by environmental tobacco smoke. Evidence from the US and 
Canada suggests that smoke-free air policies are associated 
with a significant reduction in cigarette consumption.23,71,82 
In a report issued by the United States Environmental Pro-
tection Agency, the costs and benefits of a proposed national 
smoke-free environment act were modeled to identify its 
net benefits. The proposed policy was meant to curtail sig-
nificantly smoking in public places entered by more than 10 
people per week. The costs considered were costs of imple-
menting and enforcing the restriction, costs of building and 
maintaining smoking lounges, among other costs. The ben-
efits included savings from smoking-related medical expen-
ditures, heart diseases averted, the value of lives saved, costs 
averted by a reduction in smoking-induced fires, and gains in 
productivity.83 The net present value to society was estimated 
to fall between US$42 and US$78 billion, and this range was 
obtained by considering high and low estimates of costs and 
benefits. In another study by the Stephens et al,82 they analyzed 
the relationship between cigarette prices and no-smoking 
bylaws to the prevalence of smoking in Canada. Results from 
a comparison of price and policy differences among Canadian 
provinces showed that the tendency of being a smoker falls 
with rising cigarette prices and with widespread no-smoking 
regulations, even after controlling for age, sex, education, and 
marital status of respondents. They thus concluded that no 
smoking regulations should be accompanied by an increase 
in cigarette prices to be more effective. If either were used in 
isolation, the outcomes will likely produce a lesser impact than 
the two measures used together.
Bans on tobacco advertisement. Tobacco remains the second 
most heavily advertised product in the United States besides 
the automobile industry.23 Over the years, it has been widely 
advocated that bans be placed totally on cigarette advertise-
ments and promotional activities. In many countries, this bill 
has been a subject of controversy or debate. There are those 
who argue that a partial ban on advertisement has little or 
no effect on cigarette consumption.71,80 This is because, most 
adverts, particularly the tobacco-industry-related ones only 
reveal the brands smoked instead of the quantity smoked. In 
this sense, therefore, it is difficult to measure the impact of 
increased or reduced advertising on tobacco consumption. In 
addition, companies affected by such legislation could seek to 
utilize alternative forms of media. In an econometric study 
on high-income countries, Saffer and Chaloupka84 noted that 
comprehensive bans on tobacco advertising tend to reduce 
consumption.
Community-based intervention programs. Smoking ces-
sation programs also come in the form of community-based 
interventions to educate, inform, and assist smokers in their 
quitting attempts. According to Secker-Walker et  al,85 
a community intervention is defined as “a co-ordinated, 
multi-dimensional programme aimed at changing adult 
smoking behaviour, involving several segments of the 
community and conducted in a defined geographical area, 
such as a town, city, country, or other administrative dis-
trict” (pp. 3). These programs could range from community 
pharmacy-based interventions to group-based counseling, 
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incentive-based smoking cessation contests, use of self-help 
quit smoking kit, and, in some cases, mass media campaigns 
directed at certain communities within a defined geographi-
cal area. The aim of this section is to identify and assess 
global evidence on the effectiveness and cost effectiveness of 
such interventions.
Nine studies on community-based interventions were 
reviewed, including studies by Altman et al,44 Secker-Walker 
et al,86 Stephens et al,82 Secker-Walker et al,87,88 Lightwood 
et al,89 Hurley and Matthews,26,30 and Simpson and 
Nonnemaker.90 Altman et al, as far back as 1987, studied the 
cost effectiveness and cost distribution of three community-
based smoking cessation programs designed for use in the 
two education communities of the Stanford Five City Proj-
ect. These programs included (1) smoking cessation class 
(eight 1-hour training sessions offered to ~8–25 participants 
where several quitting techniques were taught); (2) incentive-
based smoking cessation contest (a 6-week community smok-
ing cessation prize contest where entrants were assessed and 
rewarded on the basis of their smoking status and habits); 
and (3) self-help quit smoking kit (included tips on smoking 
replacement habits, social support available, public commit-
ment, and record keeping and goal setting, among other tips 
aimed at providing specific actions to aid individual smoking 
cessation). Results revealed that the self-help quit had the low-
est total cost (US$26,190), lowest quit rate (21%), lowest time 
requirement for participants, and was the most cost effective 
(with a CER of $50). However, the smoking cessation class 
was the most effective, requiring the most time from partici-
pants, with a quit rate of 35%, but incurring the highest total 
costs (US$261,589) and was also least cost effective (US$276). 
The smoking cessation contest was in-between the other two 
programs, with a total cost of US$82,925, a quit rate of 22%, 
and a CER of US$151.
A community pharmacy also provides an excellent set-
ting in which to provide a smoking cessation program, as the 
pharmacy would have regular contact with residents of the 
area. Thavorn and Chaiyakunapruk30 evaluated the incremen-
tal cost effectiveness of a community-pharmacist-based smok-
ing cessation (CPSC) in Thailand. They found that the CPSC 
program yielded cost savings and life year gains to the health 
system. A series of sensitivity analyses, however, demon-
strated that both cost savings and life year gains were sensitive 
to variations in discount rate and long-term smoking quit rate 
associated with the intervention (see Supplementary File 2 for 
more details on the results).
Lightwood et al89 also examined the effect of California’s 
Tobacco Control Program (CTCP) on aggregate personal 
health expenditures in the state. The CTCP, which was estab-
lished in 1989, offered a comprehensive approach to smok-
ing cessation by altering the existing social norms and values 
among tobacco users. The campaign featured an aggressive 
media campaign with three themes, namely the tobacco 
industry lies, nicotine is addictive, and second-hand smoke 
kills. It also included a radical public policy change, especially 
in the area of promoting smoke free environments. The find-
ings of the study revealed that, between 1989 and 2004, the 
California program led to a reduction in personal health care 
expenditures to the tune of US$86 billion (in 2004 dollars), 
which would have been expected without the program. Using 
95% confidence interval, the cost savings ranged between $28 
billion and US$151 billion.
Hurley and Matthews26 also presented evidence on the 
cost effectiveness of Australia’s National Tobacco Campaign 
(NTC), an intensive mass media antismoking campaign, 
which was launched in 1997. Using a quit benefits model 
(QBM), the study predicted that the NTC avoided more 
than 32,000 cases of COPD, 11,000 cases of acute myo-
cardial infarction, 10,000 cases of lung cancer, and 2,500 
cases of stroke. The model also predicted the prevention of 
about 55,000 deaths, 323,000 life-years gain, and 407,000 
QALYs, as well as a health care cost savings of AUD$740.6 
million. Thus, the NTC was both effective and cost saving.
The above studies as well as other community-based 
interventions all reveal that a strong and aggressive tobacco 
control program do not only reduce the number of smokers 
and its resulting health benefits but also reduce substantially 
the health care expenditure associated with smoking preva-
lence. It is worth noting that the benefits of these initiatives 
may not have been well established quantitatively in the sense 
that most of these studies reflect potential uncertainty in the 
estimates and data used as well as differences in the param-
eters estimated. In some cases, data sufficient to establish 
definite causality are also lacking. However, on the balance, 
the community-based cessation initiatives examined appear to 
yield substantial net benefits.
Telecoms, media, and technology-based interventions. TMT-
based interventions refer to electronic and mass media-related 
means aimed at offering support to effect changes in smok-
ing behavior in adults and young adolescents. Examples 
include telephone counseling offered through “quitlines” or 
“helplines”; radio, TV, and print media; and computer and 
Internet-based intervention programs. A summary of the 
results of related TMT-based cost effectiveness studies can be 
found in Supplementary File 2.
Telephone counselling, quitlines and text messaging. Tele-
phone services can provide information and support for 
smokers. Counseling may be provided proactively or offered 
reactively to callers to smoking cessation helplines.91 Sup-
port can be given in individual counseling sessions or in a 
group therapy where clients can share problems and derive 
support from one another. Counseling may be helpful in 
planning a quit attempt and could assist in preventing 
relapse during the initial period of abstinence. Although 
intensive face-to-face intervention increases quit rates, there 
are difficulties in delivering it to large numbers. Telephone 
counseling may be a way of providing individual counseling 
more affordably.
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Tomson et al45 examined the cost effectiveness of the 
Swedish quitline, a free-of-charge service offered to the smok-
ing population in Sweden to aid cessation. About 31% of the 
study population (354 callers) reported abstinence after 1 year 
of the implementation of the scheme, leading to an accumu-
lated number of life year saved of 2,400. The cost per quitter 
ranged between US$311 and US$401. In comparison with 
other smoking cessation interventions, the study concluded 
that the Swedish quitline was cost effective. A more recent 
study by Rasmussen40 assessed the cost effectiveness of the 
Danish smoking cessation telephone service “quitline”. The 
study was based on the number of quitline callers in 2005. 
A total 511 ex-smokers were estimated to have gained 2172 
life years based on prolonged abstinence over 12  months. 
Discounting life years (LYs) at 3% per annum, the costs per 
LYS are €213 for ex-smokers with continued abstinence 
and €137 for ex-smokers with point prevalence abstinence. 
The sensitivity analysis for a worst case scenario indicates that 
the costs per LYS are €1199. The author concluded that the 
Danish reactive telephone counseling to aid smoking ces-
sation appears to be cost effective in comparison with other 
Danish smoking cessation interventions.
Farrelly et al92 took a rather different dimension to the 
study of quitlines by assessing the relative effectiveness and 
cost effectiveness of television, radio, and print advertisements 
in generating calls to the New York smokers’ quitline. The 
results showed that there was a positive and statistically sig-
nificant association between the call volume and expenditures 
for television (P  0.01) and radio (P  0.001) advertisements 
and a slightly significant effect for expenditures on newspa-
per advertisement (P  0.065). Though television advertising 
had the largest effect on call volume, differences in advertising 
costs for different media implied that call volume on the quit-
line was least responsive to increases in expenditure on televi-
sion advertising (0.1%) per US$1000 increase compared to the 
other mass media: radio (5.7%) and newspaper (2.8%). While 
it was difficult to determine the optimal mix of expenditures, 
the bottom line is that all three mass media effectively raised 
the number of callers to the New York quitline.
Another telecom-based intervention measure is the use 
of mobile phone text messaging facilities to aid smoking ces-
sation. A study by Guerriero et al93 used a cohort simulation 
model to determine the cost effectiveness of smoking ces-
sation support delivered by mobile phone text messaging in 
the UK, called “Txt2stop”. The cost effectiveness was mea-
sured in terms of cost per quitter, cost per life year gained, 
and cost per QALY gained. The cost of text-based support 
per 1,000 enrolled smokers was £16,120, which, given an 
estimated 58 additional quitters at 6 months, equates to £278 
per quitter. However, when the future NHS costs saved (as a 
result of reduced smoking) are included, text-based support 
would be cost saving. It is estimated that 18 LYs are gained 
per 1,000 smokers (0.3 LYs per quitter) receiving text-based 
support, and 29 QALYs are gained (0.5 QALYs per quitter). 
The deterministic sensitivity analysis indicated that changes in 
individual model parameters did not alter the conclusion that 
this is a cost-effective intervention. Similarly, the probabilistic 
sensitivity analysis indicated a .90% chance that the inter-
vention will be cost saving.
Mass-media-led interventions. Mass media interventions 
consist of the dissemination through television, radio, print 
media, and billboards of cessation-related messages, inform-
ing smokers and motivating them to quit. Mass media cam-
paigns can be effective in keeping tobacco control on the social 
and political agenda, in reinforcing community action, and in 
triggering other interventions. Campaigns are designed either 
directly to change individuals’ smoking behavior (the risk fac-
tor model) or to catalyze other forces of social change (the 
social diffusion model), which may then lead to change in 
the social norms about smoking.94 Social diffusion campaigns, 
such as those run in Australia, Canada, UK, Thailand, and in 
some US states, are designed to de-normalize smoking, thus 
counteracting the tobacco industry’s message that smoking is 
desirable and harmless.
While many studies have revealed that mass media inter-
ventions are effective in reducing smoking prevalence among 
adults, not many studies have commented on the cost effec-
tiveness of such campaigns. Villanti et al95 evaluated the cost 
effectiveness of the American Legacy Foundation’s national 
“EX” campaign, which ran on radio and TV in 2008 and was 
designed to promote smoking cessation among adult smok-
ers. The incremental societal cost of EX, in 2009 dollars, was 
US$166 million. Data from eight designated media market 
areas studied indicate that, in a hypothetical nationwide 
cohort of 2,012,000 adult smokers ages 18–49, EX resulted 
in 52,979 additional quit attempts and 4,238 additional 
quits and saved 4,450 QALYs. Incremental cost-utility esti-
mates comparing EX to the status quo—that is, the situation 
that would have existed in eight markets with no campaign 
and no change in cessation behavior—ranged from a cost of 
US$37,355 to US$81,301 per QALY, which suggests that 
the campaign was cost effective. These findings are consistent 
with previous evidence that national mass media campaigns 
for smoking cessation in the US can lower smoking preva-
lence in a cost-effective manner. However, in a study on the 
cost effectiveness of online, radio, and print tobacco control 
advertisements targeting 25–39-year-old males in Australia, 
Clayforth et al42 found that online advertising could be more 
cost effective than other non-television advertising media such 
as radio and press in reaching and affecting target audiences, 
implying that online campaigns may be a highly cost-effective 
channel for low-budget tobacco control media campaigns (see 
Supplementary File 2 for details).
Computer- and internet-based programs. Personal comput-
ers, the Internet, and other electronic aids, which are now an 
indispensable part of daily life for many people around the 
world, also offer additional means of effecting changes to 
smoking behavior. These electronic-based measures have been 
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found to be effective and cost effective in reducing smoking 
prevalence among adults (see35,96,97). For example, computer-
tailored programs that entail the adaption of the content of an 
intervention to participants’ individual characteristics using 
computer programs have been found to be both effective and 
economically efficient.41 Most often, a questionnaire is used 
as a screening instrument, in which case answers provided by 
the smokers on the questions are accumulated into a large data 
file and are subsequently matched with relevant feedback mes-
sages that are ultimately combined into a tailored feedback let-
ter. Tailored interventions are more effective in attracting and 
keeping a smoker’s attention, resulting in better processing 
of information. Civljak et al97 found that Internet programs 
that were interactive and tailored to individual responses led 
to higher quit rates than usual care or written self-help at 
6 months or longer. There are two types of computer-tailored 
programs: single computer-tailored programs and multiple 
computer-tailored programs. A single-tailored feedback mes-
sage is successful in increasing cessation rates, but dynamically 
tailored feedback provided on multiple occasions can even be 
more effective. Due to the automatic generation of the tailored 
feedback and the fact that computer-tailored interventions are 
increasingly delivered online, the integration of an internet-
based computer-tailored program in the general practice 
setting might limit the burden on health professionals and 
patients, reduce facility and administrative costs, and could 
potentially be time and cost saving.41 However, the Internet 
may offer additional benefits when combined with usual phar-
macological interventions, such as NRT, varenicline, or other 
pharmacotherapy.
School-based interventions. Though the majority of 
smoking-related deaths occur in people aged 35 years or older, 
the onset of tobacco use occurs primarily in early adolescence, 
which makes adolescents a special target for smoking prevention 
projects. Schools have been identified as an ideal site to deliver 
tobacco prevention programs since they capture the majority of 
youth across a large age range, including the ages when most 
young people initiate smoking. The main perceived advantages 
of school-based intervention programs are that almost all chil-
dren can be reached through schools, and a focus on education 
fits naturally with the daily activities of schools.98 Researchers 
often employ five types of school-based intervention programs, 
each based on a different theoretical orientation: (1) information-
only curricula, ie, interventions that provide information to 
oppose tobacco use (also called normative education). These 
educational programs provide content and activities that seek 
to correct inaccurate perceptions regarding high prevalence of 
tobacco use; (2) social competence curricula, a group of inter-
ventions that aim to help adolescents refuse offers to smoke by 
improving their general social competence—including training 
on life skills such as self-control, self-esteem, decision making, 
and cognitive skills for resisting interpersonal and media influ-
ences; (3) social influence curricula, educational programs that 
seek to inform youths about the effects of outside influences 
such as advertising on their behavior, teach them that smoking 
is not the norm, and give them the skills to refuse cigarettes; 
(4) combined social competence and social influences curricula, 
methods that draw on both social competence and social influ-
ence approaches, and (5) multimodal programs, which com-
bine curricular approaches with wider initiatives within and 
beyond the school, including programs for parents, schools, 
communities, and initiatives to change school policies about 
tobacco, or state policies about the taxation, sale, availability, 
and use of tobacco.
Although numerous school-based smoking prevention 
trials have found short-term decreases in smoking prevalence 
by up to 30%–70%, there is little or no evidence on the long-
term effectiveness of school-based smoking prevention pro-
grams.98–100 Tengs et al101 have reported that the effectiveness of 
anti-tobacco education programs using the “social influences” 
model tends to dissipate in 1–4 years, raising questions about 
the long-term economic efficiency of such initiatives. Using a 
system-dynamics computer simulation model based on sec-
ondary data, the authors evaluated the cost effectiveness of an 
enhanced nationwide school-based anti-tobacco education and 
found that over 50 years, cost effectiveness is estimated to lie 
between US$4,900 and US$340,000 per QALY, depending on 
the degree and longevity of program effectiveness. Assuming 
a 30% effectiveness that dissipates in 4 years, cost effectiveness 
is US$20,000/QALY. A similar study on the cost effectiveness 
of a school-based tobacco use prevention program in the US, 
known as Toward No Tobacco Use (TNT), showed that the 
program was highly effective as the government could expect 
to save US$13,316 per LY saved and a saving of US8,482 per 
QALY saved. However, a peer-led intervention, known as 
ASSIST, aimed at reduced smoking among adolescents in 
England and Wales, was only valued to yield a modest cost 
saving, with an incremental cost per student not smoking after 
2 years of follow-up at £1,500 (CI = £669–£9,947). Other cost-
effectiveness studies on school-based smoking cessation pro-
grams are summarized in Supplementary File 2. From all of 
these studies, an issue that remains unresolved is the extent to 
which reductions in adolescent smoking lead to lower smoking 
prevalence and/or earlier smoking cessation in adulthood.
Workplace interventions. There has been growing inter-
est within the business community regarding interventions 
against smoking in the workplace. Smoking interventions in 
the workplace particularly have numerous advantages. First, 
a large number of people can be contacted, canvassed, and 
enrolled in programs with relative ease, sometimes with the 
aid of extensive onsite occupational health facilities.102 Second, 
worksites have the potential for higher participation rate 
than non-workplace environments. Third, worksites have the 
potential to provide sustained peer group support and positive 
peer pressure for quitting and staying tobacco-free. Fourth, it 
provides a particular opportunity to target young men, who 
traditionally have low general practitioner consultation rates 
and are thus less likely to benefit from opportunistic health 
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promotion activity in primary care. Fifth, in some workplaces, 
occupational health staff may be on hand to give professional 
support. Finally, the employee need not travel to attend ces-
sation programs; hence the workplace provides convenience 
benefits to the employee.103,104 It is worthy of note that many 
of these assumptions are based on a model of workplace that 
is rapidly changing. With many generation-Y employees who 
change jobs frequently or work from multiple locations, the 
net benefits from workplace cessations could be expected to 
become marginal in the long run.
Workplace smoking interventions can take numerous 
forms, including pharmacological interventions, behavioral 
interventions, or a combination of both. It could target indi-
viduals or specific employee groups. The main strategies include 
smoking prohibition, incentives, competitions, individual and 
group counseling, self-help materials, pharmacological therapy, 
and social and environmental support.
Many health economics researchers have found empiri-
cal evidence to support the general belief that smoking inter-
vention programs help a firm’s bottom line by reducing health 
care costs, absenteeism, and its attendant productivity losses 
and other employer-related costs.105 However, there are seri-
ous challenges to the reliability and validity of their findings, 
as some critics of this literature have cited systematic biases 
affecting the credibility of some of these studies. These biases 
often manifest themselves in underestimation of costs and 
overestimation of benefits. Other researchers who have carried 
out behavioral workplace interventions have found a strong 
consistency in the correlation between smoking interventions 
and reduced cigarette consumption and decreased expo-
sure to environmental tobacco smoke.106 Smedslund et al103 
also compared the cost effectiveness of behavioral workplace 
interventions compared to pharmacological interventions and 
found that controlled smoking cessation trials at the worksite 
showed initial effectiveness, but the effect seemed to decrease 
over time and was not present beyond 12  months. Jackson 
et al,107 however, showed that pharmacological interventions 
at the workplace seemed to generate 12-month employer 
cost savings per nonsmoking employee of between $150 
and $540. The authors however found that varenicline was 
more cost beneficial than placebo because it had higher quit 
rates. Warner et al105 also found that smoking cessation is 
a very sound economic investment for the firm, and is par-
ticularly profitable when long-term benefits are included, 
with an eventual benefit–cost ratio of 8.75. Other studies by 
Ong and Glantz108 also showed that the first year effect of 
making all workplaces in the US smoke-free would produce 
about 1.3 million new quitters and prevent over 950 million 
cigarette packs from being smoked annually, worth about 
US$2.3  billion in pretax sales to the tobacco industry. In 
addition to preventing the risk of smoking-induced diseases 
such as myocardial infarctions and strokes, smoke-free work 
places could result in nearly US$49 million in savings in 
direct medical costs after 1 year. At steady state, more than 
US$224 million would be saved in direct medical costs annu-
ally (see Supplementary File 2 for summary of results).
Overall, this section has examined evidence across coun-
tries on the economic impact of smoking and the effective-
ness and cost effectiveness of reducing smoking prevalence 
through intervention programs. It has examined the health- 
and non-health-related costs and benefits of smoking as well 
as the effectiveness and cost effectiveness of pharmacological, 
policy-based, community-based, TMT-based, school-based 
and workplace- or employer-based smoking cessation inter-
ventions carried out through the years by different countries 
or state public health agencies. Key statistics and examples 
were drawn from United States, China, Australia, Canada, 
Hong Kong, Belgium, Taiwan, India, France, and Sweden. 
Next, this study narrows down by reviewing the economics of 
smoking in United Kingdom.
The Economic Impact of Smoking and Smoking 
Cessation Interventions in UK
The costs and benefits of smoking in UK. Smoking has 
also been responsible for over 100,000 deaths per annum over 
the last decade in UK. The number of deaths attributable to 
smoking in 2005 was estimated at 109,164.8 The financial and 
health burden of smoking in UK is enormous. Previous studies 
have estimated the direct costs of treating smoking-related dis-
eases by the NHS to range somewhere between £1.4 and £1.7 
billion every year.10,56,109,110 A more recent study conducted 
by Callum et al12 showed that smoking-attributable costs to 
the NHS in 2006 was estimated at £2.7 billion. This includes 
smoking attributable hospital admissions (£1 billion), outpa-
tient attendances (£190 million), general practitioner (GP) 
consultations (£530 million), practice nurse consultations (£50 
million), and GP prescriptions (£900 million). Allender et al8 
estimates the costs of smoking-induced ill health to the NHS 
to be £5.2 billion in 2005–2006, representing about 5.5% of 
the total NHS budget that yeare (see also7). The cost of smok-
ing in UK is thus increasing every year. The estimates provided 
by the above studies, however, are conservative cost estimates 
because they do not include the indirect costs of passive smok-
ing and productivity losses due to smoking-related morbidity 
and premature mortality. The costs of informal care, smoking-
related fires, cleaning costs, and sickness absence payments 
were also excluded from these estimates.
Cohen and Barton56 show that approximately 50 million 
working daysf are lost in UK annually due to smoking, valued 
at £1.71 billion. The British Medical Association112 estimates 
that each year in UK, at least 1,000 deaths are attributable 
e  The cost of smoking to the NHS Wales has been estimated to be £386 million in 
2007/2008, which is equivalent to £129 per head and 7% of total health care expendi-
ture in Wales.136
f  In England and Wales, more than 34 million days are lost through sickness absence 
resulting from smoking-related ill-health, while in Scotland the cost of productivity 
loss is ~£400–£450 million. In addition, smoking-induced fires cost about £4 million 
per annum in Scotland.10,137
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to passive smoking and more than 17,000 children under the 
age of five are admitted to hospital because of the ill effects of 
second-hand smoke. Parrott and Godfrey10 have estimated that 
each year in UK the cost of treating childhood illnesses related 
to smoking is about £410 million. The same study estimates 
the damage caused by smoking-related fires to be around £151 
million each year in England and Wales. If all these indirect 
costs estimates are included to the NHS figures, the financial 
burden of smoking in UK will skyrocket. A more recent report 
by the Policy Exchange in 2010 attempts to sum up the total 
estimated costs to society of smoking in UK and puts the figure 
at £13.74 billion. This includes £2.7 billion cost to the NHS 
but also the loss in productivity from smoking breaks (£2.9 
billion), and increased absenteeism (£2.5 billion). Other costs 
include cleaning up cigarette butts (£342 million), the cost of 
fires (£507 million), the loss of economic output from the death 
of smokers (£4.1 billion), and passive smokers (£713 million).
The study by Allender et al8 shows the percentage attrib-
utable to smoking of total NHS costs for smoking-related 
conditions in 2005–2006 by countries in UK (see Table  1). 
In  England, the cost of smoking is £4.3 billion and this 
 represents about 85% of the total smoking attributable costs 
in UK. For Wales, Scotland, and Northern Ireland, smok-
ing-attributable cost was £234.2 million, £409.4 million and 
£127.9 million, respectively. Following the analysis made by 
this study, the smoking-attributable fraction (SAF) in UK was 
estimated at 23%. The SAF represents the costs attributable 
to smoking for smoking-related conditions, as a proportion 
of total NHS expenditure for those conditions. The smoking-
related conditions considered included cardiovascular diseases, 
COPD, other respiratory conditions, lung/bronchus/trachea 
cancer, mouth and oral cancer and peptic ulcer disease.
In spite of the costs of smoking in UK, there are potential 
economic benefits that smoking brings to the economy. Just 
like in other countries, tobacco is a major revenue earner for 
the government. Thus, a reduction in the prevalence of smok-
ing will bring about significant loss to the Exchequer. Accord-
ing to the HM Revenue and Customs112 Tobacco Bulletin and 
Factsheets, the treasury earned £9.5 billion in revenue from 
tobacco duties in the financial year 2011–2012 (excluding 
VAT). This amounts to 2% of the total government revenue. 
Including VAT at an estimated £2.6 billion, total tobacco 
revenue was £12.1 billion.113 The price of a pack of 20 pre-
mium brand cigarettes currently costs around £7.98, of which 
£6.17 (or 77%) is tax.114 The economic benefits of smoking 
from taxation alone thus appear to be noticeably higher than 
the direct costs of smoking in UK. A CBA of the effects of 
increasing tobacco taxation commissioned by ASH (in115) 
found that a tobacco price increase of 5% would result in net 
benefits to the economy as a whole of around £10.2 billion over 
50 years. The economic benefits in the first 5 years would be 
around £270 million per year on average.
Apart from government taxation, tobacco companies 
make huge profits from sale of tobacco products. In 2012, 
British American Tobacco, which is the world’s second largest 
tobacco company, produced 694 billion cigarettes worldwide 
(down from 705 billion in 2011) and reported an operating 
profit of £5.14 billion, an increase of 15% on 2011.116 The 
two major UK tobacco companies—Imperial Tobacco and 
Gallaher (the latter now owned by JTI)—control around 85% 
of the UK market.
The economic benefits of smoking in UK could also be 
seen in terms of employment in the tobacco and dependent 
industries. According to the National Statistics from Tobacco 
Manufacturers Association,117 approximately 5,700 people are 
employed in tobacco manufacturing in UK. It has been argued 
that a reduction of smoking might not necessarily imply an 
overall increase in unemployment. It may well boost employ-
ment and output.56,118,119 The argument is that, though there 
will be loss of job in the tobacco industry following smoking 
cessation, money not expended on tobacco will then be spent 
elsewhere, thereby increasing the demand for other goods and 
services, and hence generating employment for some other 
sectors. The extent, to which this happens, however, depends 
on the spending patterns of the former smokers. McNicoll 
and Boyle118 estimated that a total cessation of cigarette pur-
chases in Glasgow will bring about net benefits to the Scottish 
economy. They estimated that for every £1 million reduction 
in cigarette expenditure, there would be a net increase in 
Scottish output of £1.1 million and a net increase of Scottish 
employment of 64 jobs. In a similar study by Buck et al,119 
a 40% reduction in smoking—a target set by the 1992 UK 
Table 1. Percentage of nhs costs attributable to smoking in 2005–2006 by countries in UK.8
COUNTRY COSTS ATTRIBUTABLE  
TO SMOKING (£ MILLION)
TOTAL NHS COSTS FOR SMOKING-
RELATED CONDITIONS*
SMOKING-ATTRIBUTABLE 
FRACTION (SAF)
england 4,398.90 19,392.60 0.23
scotland 409.4 1,805.10 0.23
Wales 234.2 1,032.7 0.23
northern Ireland 127.9 563.7 0.23
Total 5,170.40 22,794.10 0.23
Note: *The smoking-related conditions considered included cardiovascular diseases, coPD, other respiratory conditions, lung/bronchus/trachea cancer, mouth and 
oral cancer and peptic ulcer disease.
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 Policy document—will have estimated effects of increasing 
jobs in the UK by 150,000. As noted earlier, a smoking popu-
lation also has the benefit of achieving savings in pension pay-
ments from the premature death of smokers. Manning et al120 
have estimated that every pack of cigarettes smoked reduces 
the life expectancy by 137 minutes and pension costs by $1.82.
The effectiveness and cost effectiveness of UK-specific 
smoking cessation programs. This section takes a look at the 
effectiveness and cost effectiveness of smoking cessation inter-
ventions that are specific to the UK and identifies where there 
are any cost savings or net benefits to the health care system 
arising from a reduction in smoking prevalence. It reviews 
high-quality evidence on the economics of smoking cessation 
programs implemented in the different parts of UK. In 1998, 
the UK government for the first time took a comprehensive 
approach to the reduction of smoking prevalence in England 
when it published a policy paper (called a White Paper), Smok-
ing Kills. This program was aimed at reducing smoking among 
children and adolescents, and help adult smokers, particularly 
the disadvantaged ones (including pregnant women) to quit 
smoking. The strategy involved ban on tobacco advertising, 
further increases in tobacco pricesg, measures to reduce smok-
ing in workplaces and in public places, measures to restrict the 
sale of tobacco to minorsh, and also, for the first time in the 
history of NHS, the commitment of huge resources to smok-
ing cessation treatment services. Smoking Kills has been able to 
reduce the average prevalence of smoking in adults (16 years+) 
in England from 27% before the implementation period to 
21% in 2008.121
NHS smoking cessation treatment services. The White 
Paper, Smoking kills, sets out guidelines for the provision of 
specialist smoking cessation services. The United Kingdom 
was the first country to introduce a national smoking cessa-
tion treatment program funded through public taxes.122 Since 
then, other countries have implemented similar treatment 
services, eg, Japan and Taiwan. Since 2000, many smokers 
have received behavioral support through counseling or spe-
cial training sessions to aid smoking cessation. In England 
and other parts of UK, smokers can purchase NRT products 
from local pharmacies and shops. A report from the National 
Institute for Clinical Excellence (NICE)123 in March 2002 
showed that NRT and bupropion are some of the most cost-
effective treatments of all pharmacological interventions. 
Their cost effectiveness has been estimated by NICE in terms 
of cost per life year gained (LYG); NHS treatment services 
produce a cost of about £3000 per LYG and about £2000 
g  One major issue associated with tax increases is that of smuggling and tax evasion. 
In the UK, it is estimated that approximately 40% of cigarettes do not have UK duty 
paid on them. The average cost of such cigarettes is almost half the price of legitimate 
ones. Taxation policies therefore need to be accompanied by a radical law enforcement 
mechanism in order to reduce this problem.122
h  Like in many countries, the UK government forbid children under the age of 16 from 
purchasing tobacco products. However, the effectiveness of this restriction has been 
called to question as children are able to obtain cigarettes from their older friends, 
siblings, or vending machines.
when adjusted using UK discount rates (estimates cited in 
Ref. 124, pp. 5). Stapleton125 reveals that calculations based 
on the reported performance of the NHS specialist smoking 
cessation services suggest they are highly cost effective, gen-
erating a cost of less than £800 per life-year saved. The same 
study reveals that during April 2000 and March 2001, about 
126,800 smokers made an attempt to quit smoking while 
attending cessation services. Of these, 48% were abstinent 
at the end of 4  weeks. The total costs (including treatment 
and administrative costs) were £21.4 million or £209 when 
expressed per patient treated.
According to a more recent report for 2005, an esti-
mated 2 million smokers in UK used NRT products (and to a 
much lesser extent bupropion) to aid in stopping smoking.122 
The effectiveness of these treatment services has also been 
estimated at ~2%–3% abstinence rates. In all, about 90,000 
smokers (out of an estimated 12 million smokers in UK) 
stopped smoking permanently in 2005, implying that about 
0.75% of smokers became ex-smokers due to smoking cessa-
tion treatments.
Two very recent studies have also examined the cost 
effectiveness of NRT, bupropion, and varenicle for preventing 
or reducing relapse to smoking by abstinent smokers following 
smoking cessation.27,126 Their findings revealed that, like other 
interventions, relapse prevention interventions (RPIs) are also 
likely to be highly cost and clinically effective. When com-
pared to no intervention, using bupropion for relapse preven-
tion resulted in an incremental QALY increase of 0.07 with 
a concurrent NHS cost saving of £68; NRT and varenicline 
both caused incremental QALY increases of 0.04 at costs of 
£12 and £90, respectively. Extensive sensitivity analyses from 
both studies demonstrated that cost-effectiveness ratios were 
more sensitive to variations in RPI effectiveness than cost. In 
addition, even after varying key model parameters, the cost 
effectiveness of NRT and bupropion generally remained. 
Cost effectiveness ratios only exceeded the UK NICE bench-
mark of £20,000 per QALY when drug treatment effects were 
projected to last for only 1 year.
In summary, NHS treatment services and relapse pre-
vention intervention services have been both clinically and 
cost effective, generating substantial health and cost savings 
that are acceptable to health care providers.
Community pharmacy-based smoking cessation. Crealey 
et al127 have looked at the cost effectiveness of a community 
pharmacy-based smoking cessation program in Northern 
Ireland. Data from a pilot study conducted in two commu-
nity pharmacies in Belfast were used as the basis of the cur-
rent study, which examined the costs and effects associated 
with a formal counseling program for smoking cessation by 
community pharmacists across Northern Ireland. The Phar-
macists Action on Smoking (PAS) model was the only active 
intervention used in the study. Findings indicate that the cost 
per life year saved when using the PAS program ranges from 
£196.76 to £351.45 in men and from £181.35 to £772.12 for 
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women (1997 values), depending on age. This compares favor-
ably with other disease prevention medical interventions such 
as screening for hypertension or hypercholesterolemia. More 
recently, Boyd and Briggs128 examined the cost effectiveness 
of pharmacy-based versus group behavioral support in smok-
ing cessation services in Glasgow. This study was based on 
the premise that smokers attending group-based support for 
smoking cessation are significantly more likely to be success-
ful than those attending pharmacy-based support. The study 
was conducted using a combination of observational study 
data and information from the NHS Greater Glasgow and 
Clyde smoking cessation services. Findings revealed that 
incremental cost per 4-week quitter for pharmacy-based sup-
port was found to be approximately £772 and £1612 for group 
support, dismissing the earlier hypothesis. Furthermore, esti-
mated incremental cost per QALY for pharmacy-based ser-
vice is £4400 and £5400 for group support service. The study, 
however, concludes that both group support and pharmacy-
based support for smoking cessation are highly cost effective.
Action Heart promotion program. Action Heart is a cost-
effective, community-based heart promotion project, which 
was implemented between 1991 and 1995 in Wath and 
Swinton, England. Baxter et al129 carried out a prospective 
comparative study to establish whether this community-
based coronary heart disease health promotion intervention, 
undertaken over 4 years, was associated with a reduction in 
the prevalence in adults of risk factors associated with heart 
disease, including smoking, as well as to estimate the cost 
effectiveness of this intervention. Smoking prevalence before 
and after the intervention was assessed using a questionnaire 
mailed to residents in both the intervention and control areas. 
Smoking decreased in the intervention area and increased in 
the control area between 1991 and 1995. Results showed that 
the intervention achieved a smoking abstinence rate of 6.9%, 
while 8.7% more of the sample population consumed low-fat 
milk between the intervention and control area in the 4-year 
period. The differences between the areas rose from 4.2% to 
9.2%. Total project cost (including allowances for community 
project officer and worker, consumables and other overheads, 
other NHS staff, school expenditure, etc) was £110,000. The 
estimated cost per life year gained was £31.
Heart beat wales (HBW). Phillips and Prowle22 also 
appraised the economics of a no-smoking intervention pro-
gram named Heart Beat Wales (HBW) carried out between 
1985 and 1988. Health benefits were estimated as inter-
mediate and final outcomes. Intermediate outcomes were 
the reduction in the number of smokers and the amount of 
tobacco consumed. The final outcomes were presented in the 
terms of reduced morbidity and mortality in three disease 
groups—coronary heart disease (CHD), lung cancer, and 
chronic bronchitis. The program costs included direct cash 
costs and staff costs. Total cost in year 1 was £72,000, in year 2 
£82,000, in year 3 £150,000, and in year 4 £205,000. Results 
show a net present value of benefits to NHS of £4,134,000. 
The “economic” appraisal has a present value of benefits of 
£43,503,000. The estimated cost of a working life year saved 
is £5.78. The net present value of benefits from reductions in 
smoking is significantly greater than costs in terms of both the 
NHS and the economy as a whole in Wales. In addition, the 
net costs per life year saved reveals that the program generates 
additional working life years at relatively low cost.
No smoking day. More than two decades after the launch 
of the “No Smoking Day” (NSD) in UK, Owen and Youdan130 
and Kotz et al131 evaluated the impact and relevance of this 
national awareness day. Launched in 1984, the campaign 
seeks to create an enabling environment for smokers to quit 
smoking. When the campaign began, smoking prevalence in 
the UK was more than 33% of adults; in 2003 it dropped to 
25%. The campaign expenditure ranges somewhere between 
£470,000 and £550,000 annually. Results show that follow-up 
after 1 week indicates awareness of NSD is lower in 2004 than 
in 1986, 2 years after it was launched. However, awareness is 
still high at 70% for all smokers. Interestingly, the decline in 
participation from 18% of aware smokers in 1994 to 7% in 
2001 was reversed in 2005 when about 19% either gave up 
or reduced their smoking on NSD. In 2004, NSD awareness 
had reached 78% of the smoking population. When compared 
to the 8.5 million smokers in England, the campaign can be 
deemed to be effective in reaching its target audience. In addi-
tion, media coverage has increased regardless of the fact that 
the campaign expenditure has remained relatively constant 
and calls to national smokers’ helpline on NSD are typically 
four times those received on a normal day. The cost of NSD 
per smoker was £0.088. The discounted life years gained per 
smoker in the modal age group 35–44  years was 0.00107, 
resulting in an incremental cost–effectiveness ratio (ICER) of 
£82.24 (95% CI 49.7–231.6). Thus, the campaign emerges as 
an extremely effective and cost-effective public health inter-
vention in aiding smoking cessation.
HEBS’s mass media-led intervention. Ratcliffe et al132 eval-
uated the costs and outcomes of a mass media-led antismoking 
campaign in Scotland, which was conducted by the Health 
Education Board for Scotland (HEBS). The campaign had 
three elements or features, namely 1) mass media advertising, 
including television, outdoor posters, and press; 2) Smokeline, 
a free telephone quitline to aid smoking cessation; and 3) You 
can stop smoking, a practical handbook aimed at guiding smok-
ers to renounce smoking. At the end of a 12-month period, 
about 9.88% of individuals in the follow-up sample reported 
they have renounced smoking since 6 months after the cam-
paign. The costs of the campaign (including the youth cam-
paign costs) ranged from £1,486,101 to £1,546,420. In terms 
of costs per quitter, estimates ranged from £189 to £369. The 
costs per life year saved attributable to the campaign ranged 
from £304 to £656. Another mass media campaign based on 
behavior change theory and operating through both tradi-
tional and new media, known as Stoptober, was launched in 
England during late 2012. Brown et al133 found that Stoptober 
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was both effective and cost effective, as it generated up to 
350,000 quit attempts and saved 10,400 discounted life years 
(DLY) at less than £415 per DLY in the modal age group.
This section has reviewed the economic impact of smok-
ing and reducing its prevalence in UK. Though smoking is 
beneficial to the UK both in terms of tax revenue and employ-
ment, the health- and non-health-related costs of smoking to 
the NHS and the society far outweigh any benefits that might 
be accruable at least from a socially desirable perspective. Most 
smoking cessation interventions implemented in the UK have 
also been highly effective, reducing the number of smokers 
and any health risks associated with smoking.
Discussion
This study reviews major studies on the economics of tobacco 
smoking and the economic impact of reducing its prevalence 
both globally and in UK. The findings from the review reveal 
that tobacco smoking is the cause of many preventable dis-
eases and premature deaths in UK and around the world. It 
poses enormous health- and non-health-related costs to the 
affected individuals, employers, and the society at large. The 
WHO estimates that, globally, smoking causes over US$500 
billion in economic damage each year. In the UK, the total 
estimated costs of smoking to society could be put at £13.74 
billion. In the US, a much larger economy by population and 
GDP, the social cost of smoking is more than 8 times that of 
UK—US$193 billion (or ~£114 billion) according to estimates 
from Kahende et al,5 though this figure is even larger when 
we consider latest estimates from the Campaign for Tobacco-
Free Kids, which puts the social cost of smoking at US$321 
billion.59 About 15% of the aggregate health care expenditure 
in high-income countries can be attributed to smoking. In the 
US, the proportion of health care expenditure attributable to 
smoking ranges between 6% and 18% across different states. 
In the UK, the direct costs of smoking to the NHS have been 
estimated at between £2.7 billion and £5.2 billion, which is 
equivalent to around 5% of the total NHS budget each year. 
The economic burden of smoking estimated in terms of GDP 
reveals that smoking accounts for approximately 0.7% of 
China’s GDP and approximately 1% of US GDP. As part of 
the indirect (non-health-related) costs of smoking, the total 
productivity losses caused by smoking each year in the US 
have been estimated at US$151 billion. Smoking is there-
fore considerably expensive to countries where its prevalence 
is high, particularly high-income countries. The costs not-
withstanding, smoking has some potential economic benefits 
to most economies. The economic activities generated from 
the production and consumption of tobacco provides eco-
nomic stimulus. It also produces huge tax revenues for most 
governments, especially in high-income countries, as well as 
employment in the tobacco industry. Income from the tobacco 
industry accounts for up to 7.4% of centrally collected govern-
ment revenue in China. Smoking also yields cost savings in 
pension payments from the premature death of smokers.
Several measures have been undertaken by most countries 
(including UK) over the years in order to reduce the preva-
lence of smoking in adults, children, and pregnant women. 
These measures range from pharmacological treatment inter-
ventions (such as the use of NRT, bupropion, and varenicle) 
to policy-based measures (tax increases, smoking restrictions, 
bans on tobacco advertising, etc), community-based inter-
ventions (such as smoking cessation contests, classroom edu-
cation, self-help quit kit, etc), TMT-based measures (such 
as quitlines, mass media led interventions, internet- and 
computer-based measures), school-based measures, and work-
place interventions. We now discuss some of the findings 
from the review by comparing results across types of interven-
tion, implementation countries, and measurement outcomes, 
where possible.
Comparing the effectiveness and cost effectiveness of 
various interventions. From the review of pharmacologi-
cal and medical treatment interventions for smoking cessa-
tion across countries, it was found that cost per life year saved 
ranged between US$128 and US$1,450 and up to US$4,400 
per QALY saved. Comparing various types of pharmaco-
logical interventions, existing studies showed that varenicline 
(with or without behavioral interventions) seemed to be the 
most cost-effective therapy, followed by bupropion and NRT. 
However, the results have a high risk of bias because the man-
ufacturer of varenicline funded most of the studies comparing 
varenicline with bupropion or NRT. In the UK, it was found 
that the use of NRT and/or bupropion combined with GP 
counseling was both clinically effective and cost effective to 
primary health care providers.
Some studies reveal that pharmacological treatments tend 
to yield more positive results in terms of number of quitters than 
other cessation interventions (eg, NRT programs could yield as 
much as 18,500 quitters at a cost of US$4,440 per QALY com-
pared to implementing a smoke-free workplace policy, which 
would generate 10,400 quitters at US$506 per QALY). The 
use of pharmacotherapies such as varenicline when combined 
with other behavioral treatment interventions (such as proac-
tive telephone counseling and Web-based delivery, or both) 
is cost effective when measured from both cost per LY and 
cost per QALY, with costs per additional 6-month nonsmoker 
and per additional life time quitter ranging from US$1,278 to 
US$1,617 and from US$2,601 to US$3,291, respectively.
With respect to policy-based measures, increase in 
tobacco taxes is unarguably the most effective means of reduc-
ing the consumption of tobacco and hence the health care costs 
associated with treating smoking-caused diseases. Findings 
show that a 10% tax-induced cigarette price increase anywhere 
in the world reduces smoking prevalence by between 4% and 
8%. Apart from reducing the number of smokers and saving 
lives, increasing tobacco taxes also raise government revenue 
accruable from tobacco manufacturers and retailers. Thus, as 
cigarette taxes increase, government tax revenues continue 
to rise even as smoking prevalence falls. In fact, net public 
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benefits from tobacco tax remain positive only when tax rates 
are between 42.9% and 91.1%. However, increase in tobacco 
taxes increases the risk of reduction in employment in tobacco 
companies and the incidence of cigarette smuggling and tax 
evasion, further dwindling the net benefits from tax increases. 
Non-price-based measures (such as smoking restrictions in 
work places, public places, bans on tobacco advertisement, and 
raising the legal age of smokers) have also proven to be both 
effective and cost saving. The health and economic benefits 
of such measures include reduction in smoking prevalence, 
reduction in second hand smoke, savings from smoking-
related medical expenditures, heart diseases averted, costs 
averted by a reduction in smoking-induced fires, and gains in 
productivity. Findings show that the cost–effectiveness ratio 
of implementing non-price-based smoking cessation legisla-
tions range from US$2 to US$112 per LYG, while reducing 
smoking prevalence by up to 30%–82% in the long term (over 
50-year period).
From the perspective of the public health system, 
community-based intervention programs yield cost savings 
and life year gains. There are, however, differences in the effec-
tiveness and cost effectiveness of different types of commu-
nity-based interventions. Smoking cessation classes are known 
to be most effective among community-based measures since 
they require more time commitment from participants. They 
could lead to a quit rate of up to 35%, but they usually incur 
higher costs. On the other hand, self-help quit smoking kits 
usually require the lowest time commitment from participants 
and are usually the most cost effective. Community pharmacies 
also provide opportunities for regular contact with residents of 
a local community. On average, community pharmacist-based 
smoking cessation programs yield cost savings to the health 
system of between US$500 and US$614 per LYG. Knowledge 
of the health and economic gains of different community-
based measures is highly desirable when health policy decision 
makers plan the allocation of resources for smoking cessation 
at the community level. One classic example of an effective 
community-based campaign is the UK’s “No Smoking Day”. 
After almost three decades of its launch, the campaign has 
achieved a 78% awareness rate. It has also reduced smok-
ing prevalence by 14%. With the cost of NSD per smoker at 
£0.088 and ICER of £82.24, NSD emerges as an extremely 
cost-effective public health intervention.
Since many people are ambivalent about smoking, it has 
been widely held that advertising media, telecommunications, 
and other technology-based interventions usually have posi-
tive synergistic effects. In fact, as many studies show, an inte-
grated approach involving a combination of multiple media 
to deliver a message produces greater effects than relying on 
one medium alone. However, the outcomes on the effective-
ness and cost effectiveness of TMT-based measures have 
been inconsistent. For example, Farrelly et al92 examined the 
effects of expenditure on TV, radio, and print advertising and 
concluded that, while TV advertising produced the greatest 
overall increase in calls to a Quitline, incremental increases 
in expenditure on radio advertising yielded proportionally 
higher increases in the call rate. Clayforth et al42 found that 
online-only advertising campaigns can be substantially more 
cost effective than other non-television advertising media 
such as radio, and print media, including when an integrated 
approach is used. Chen et al34,35 also found that making some 
form of electronic support available to smokers actively seek-
ing to quit (eg, PC, internet, and other electronic aids) is 
highly likely to be cost effective. This is true whether the elec-
tronic intervention is delivered alongside brief advice or more 
intensive counseling.
The differences in reported cost effectiveness may be partly 
attributed to varying methodological approaches, including 
different inputs used to determine model parameters, espe-
cially the different dependent variables tested (eg, calls to a 
quitline versus intention to quit; visits to a quit website versus 
online registration to smoking cessation services), disparate 
levels of resourcing between campaigns, differences in nati-
onal contexts, and differences in advertising campaigns tested 
on different media. For example, radio is limited to sound, 
while traditional print media is confined to static pictures. 
Further, it is difficult to isolate the effects of individual media 
due to the tendency for campaigns to typically involve the 
simultaneous use of different media to optimize results. In 
such circumstances, it is difficult to attribute results to spe-
cific media. Some studies have, however, shown that under 
a wide variety of conditions, the use of personalized smok-
ing cessation service advice, when combined with telephone 
counseling, mobile phone messages, or other personalized 
computer-based intervention measures, is both beneficial for 
health and cost saving to a health system.
In evaluating the effectiveness of school-based interven-
tion programs aimed at preventing smoking in children and 
adolescents, many studies have conducted analysis of peer-led 
programs, analysis of social influences, social competences, 
gender effects, class competitions, and booster sessions, among 
other measures. Thomas et al98 found that all these theoreti-
cal approaches were very effective in aiding smoking cessa-
tion particularly in the number of youths that were prevented 
from starting smoking. Numerous smoking prevalence trials 
have found short-term decreases in smoking prevalence of 
between 30% and 70%. As with other intervention programs, 
determining that a program is effective may not be sufficient to 
justify its implementation since the resources to fund school-
based smoking prevention programs are limited. Because of 
limited financial resources, most school-based smoking ces-
sation programs are usually carried out in multiple schools, 
most times covering thousands of students across communities 
or regions within the countries of implementation (eg, TNT 
in USA; ASSIST in England and Wales; MYTRI in India; 
SFC in Germany). Total intervention costs could range from 
US$16,400 to US$580,000 depending on the scale and scope of 
intervention, and these costs usually cover personnel expenses, 
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costs of materials, travel expenses, and program administra-
tion costs. Most studies evaluating the cost effectiveness of 
school-based programs show that one could expect a saving of 
approximately between US$2,000 and US$20,000 per QALY 
saved due to averted smoking after 2–4 years of follow-up.
Finally, from the economic evaluation of smoking ces-
sation activities at the workplace, it is evident that employer-
based interventions could be beneficial to both employers 
and the society at large. For example, Warner et al105 found 
that smoking cessation is a very sound economic investment 
for the firm, and is particularly profitable when long-term 
benefits are included, with an eventual benefit–cost ratio 
of 8.75. Jackson et al107 also showed that pharmacological 
interventions at the workplace seemed to generate 12-month 
employer cost savings per nonsmoking employee of between 
$150 and $540. Other studies by Ong and Glantz108 also 
showed that the first-year effect of making all workplaces 
in the US smoke-free would produce about 1.3 million new 
quitters and prevent over 950 million cigarette packs from 
being smoked annually, worth about US$2.3 billion in pretax 
sales to the tobacco industry. In addition to preventing the 
risk of smoking-induced diseases such as myocardial infarc-
tions and strokes, smoke-free work places could result in 
nearly US$49 million in savings in direct medical costs after 
1 year. At steady state, more than US$224 million would be 
saved in direct medical costs annually.
From a review of these and other economic studies, it 
can be safely deduced that the economic benefits of employer-
based smoking cessation measures are likely to be far more 
greater than the costs involved, particularly on a long-range 
basis, since reduced worksite smoking prevalence trans-
lates into reduced absenteeism, increased productivity, lower 
health insurance costs, higher cost savings, and higher overall 
benefit–cost ratio in the long run. Moreover, the economic 
advantages of workplace anti-tobacco policies seem to be more 
visible when smoking at the workplace is completely prohib-
ited and no smoking areas are set.
Limitations of the study. Only a few studies examining the 
long-term effect of smoking cessation interventions were found. 
Evidence of long-term health and economic benefits of many ces-
sation interventions such as clinical and workplace interventions 
remains uncertain. A series of sensitivity analyses from many of 
the studies also show that both cost savings and life year gains 
are sensitive to variations in the discount rates and the long-term 
smoking quit rate associated with the intervention. Thus, there is 
a high risk of uncertainty in some of the cost estimates provided in 
this study. Another source of error in comparative analysis is the 
differences in basis for cost comparisons across countries and the 
impact of inflation on cost estimates. For example, there are sig-
nificant differences across countries in terms of basic demographic 
and socioeconomic characteristics, life expectancy of population, 
and advancements in health care systems. Thus, calculation of 
life years saved and medical costs of smoking-related diseases are 
likely to differ significantly across countries. Also, the inflation 
rates in developing/emerging countries like India, Thailand, Tai-
wan, and China are likely to be higher than those in developed 
countries such as USA, UK, Canada, and Australia where infla-
tion rates are known to be somewhat lower. Hence, some studies 
may overstate the real cost estimates if not properly discounted (ie, 
adjusted) for inflation, thus making comparisons across time and 
countries difficult. Finally, it is worth noting that the results of 
many studies reviewed may not have been well established quan-
titatively in the sense that most of these studies reflect potential 
uncertainty in the estimates and data used and, in some cases, data 
sufficient to establish definite causality are lacking.
Conclusions
Though tobacco smoking may be economically beneficial, its 
direct costs and externalities to society far outweigh any ben-
efits that might be accruable at least when considered from 
the perspective of socially desirable outcomes (eg, a healthy 
population and a vibrant workforce). There are enormous 
differences in the application and economic measurement of 
smoking cessation measures across various types of interven-
tions, methodologies, countries, economic settings, and health 
care systems, and these may have affected the comparability of 
the results of the studies reviewed. However, on the balance 
of probabilities, most of the cessation measures reviewed have 
not only proved effective but also cost effective in delivering 
the much-desired cost savings and net gains to individuals and 
primary health care providers.
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 o
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r p
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 p
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ra
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r l
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at
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at
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 c
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